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 Parkinson’s  disease  (PD)  is  the  most  common  neurodegenerative  movement disorder  first  characterized  in  1917  by  James  Parkinson,  who  called  it  the  “shaking palsy”. The pathogenesis of PD has not yet been elucidated, as it is a complex and multi‐factorial  disease.  PD  is  characterized  by  the  progressive  and  selective  loss  of dopaminergic  neurons  within  the  substantia  nigra.  Both  motor  and  non‐motor symptoms  are  seen  in  patients  with  PD,  including  bradykinesia,  rigidity,  postural instability, depression, olfactory deficits, and dementia.  Idiopathic PD, which accounts for approximately 95% of known PD cases, is age‐related and affects approximately 3% of  people  over  the  age  of  65.  The  pathology  of  PD  was  once  believed  to  be  simple, involving selective degeneration of the nigrostriatal pathway leading to the reduction of the  nigrostriatal  region’s  dopamine  concentration.  But  the  pathology  of  PD  has  been found  to  be much more  complex, with  evidence  of  degeneration  of  nondopaminergic transmitter systems as well as dopaminergic neurons. Over the years, new pathogenic mechanisms  have  been  studied  and  implicated  in  the  pathology  of  PD,  including neuroinflammation,  reactive  microgliosis,  oxidative  stress,  and  mitochondrial dysfunction.   Recent  studies  evaluating  exposure  to  transition  metals  have  shown  that manganese  (Mn),  by  itself  or  in  combination  with  an  inflammatory  stimulus,  can activate  pathways,  leading  to  a  neuroinflammatory  response  within  the  nigrostriatal dopaminergic system. Our  lab has previously shown that the novel PKC isoform PKCδ contributes  to  manganese‐induced  apoptosis.  When  catalytically  cleaved,  PKCδ 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activates caspase‐3, which consequently activates caspase‐9, leading to the activation of an  apoptotic  cascade.  Previous  studies  by  other  laboratories  showed  that  Mn  can augment  neuroinflammatory  responses,  including  LPS‐induced  neuroinflammatory responses.  We  sought  to  investigate  if  PKCδ  plays  a  role  in  LPS/Mn‐induced inflammatory events using in vitro models of neuroinflammation. We showed increases in nitric oxide release, gp91phox protein expression, and the production of intracellular reactive oxygen species upon Mn/LPS treatment, which could be attenuated when cells were  pretreated  with  the  PKCδ  inhibitor  rottlerin.  We  also  used  primary  microglia obtained from both wild‐type mice and PKCδ knockout mice as a cell culture model of neuroinflammation.  The  primary microglia were  treated with Mn/LPS  and we  saw  a marked  decrease  in  the  release  of  nitric  oxide,  production  of  intracellular  reactive oxygen  species,  and  the  release  of  various  cytokines  (IL‐1β,  IL‐6,  IL‐10,  IL‐12,  and TNFα)  in  the  PKCδ  (‐/‐) microglia  as  compared  to  the microglia  obtained  from wild‐type mice. Collectively, our results suggest that the PKCδ signaling pathway may play a key  role  in  regulating  key  proinflammatory  events,  including  microglial  activation, cytokine  release,  and  NADPH  oxidase  complex  activity  induced  by  LPS/manganese treatment.   Our lab also studied the novel compound diapocynin, a metabolite and dimer of the naturally occurring NADPH oxidase  inhibitor apocynin, and its ability to attenuate LPS/Mn‐induced  neuroinflammatory  events.  Initially,  we  compared  apocynin  and diapocynin  side‐by‐side  to  determine  if  diapocynin  could  effectively  block neuroinflammatory  events. We  found  that  diapocynin  had  an  EC50  about  eight  times 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 The alternative format was used for this thesis. It consists of an overall abstract, a  general  introduction,  three  research  papers,  a  general  conclusion,  references,  and acknowledgments. The abstract introduces the research project discussed in this thesis. The  general  introduction  chapter  contains  a  brief  overview  of  idiopathic  Parkinson’s disease. The background and literature review section introduces reactive microgliosis and  current  evidence  demonstrating  the  role  it  plays  in  Parkinson’s  disease.  It  also reviews what is currently known about protein kinase C delta (PKCδ) and the role this protein  plays  in  dopaminergic  neuronal  degeneration  and  neuroinflammatory processes.  Also  the  review will  outline what  is  known  about  diapocynin  and  current uses  against  inflammatory  events.  The  background  and  literature  review  section will end with the research objectives pertaining to chapters II, III, and VI. Chapters II, III, and IV are  research papers, which will be  communicated  to different  journals. References for  each  of  these  chapters will  be  at  the  end  of  the  corresponding  chapter.  The  fifth chapter will be general conclusions pertaining to the findings in the previous chapters. References  used  for  the  introduction,  background  and  literature  review,  and  general conclusions  sections  will  be  in  the  final  references  section.  The  final  section  will  be acknowledgements.   All of the research in this thesis described by the author was obtained during the course  of  her  graduate  studies  at  Iowa  State  University  under  the  guidance  and 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Introduction   Parkinson’s  disease  (PD)  is  the  second  most  common  neurodegenerative disorder  and  the most  common neurodegenerative movement  disorder  and was  first described  by  James  Parkinson  in  1817  as  the  “shaking  palsy”.  The  disease  is characterized by the progressive and selective loss of dopaminergic neurons within the substantia  nigra.  PD  is  characterized  by  a  variety  of  motor  deficits  including bradykinesia,  akinesia,  rigidity,  and postural  instability,  as well  as  various non‐motor symptoms  ranging  from  depression  and  sleep  disorders  to  dementia.  This  disease affects  approximately  1  million  people  in  the  United  States  and  more  the  4  million worldwide (von Bohlen und Halbach, Schober et al. 2004). Idiopathic PD, which occurs in  95%  of  PD  cases  (Tanner  2003),  is  age‐related  and  affects  approximately  3%  of people of the age of 65 (Whitton 2007).  
  The  pathology  of  PD  was  often  considered  simple,  involving  the  nigrostriatal pathway  selective degeneration  resulting  in  the  reduction of dopamine  concentration within  the  nigrostriatal  region.  Unfortunately,  the  pathology  of  PD  is  much  more complex,  and  includes  degeneration  of  nondopaminergic  transmitter  systems  as well (Lang  and  Obeso  2004).  As  neurodegenerative  research  branches  into  new  areas, various  pathogenic  mechanisms  have  been  implicated  in  PD:  neuroinflammation, reactive microgliosis, ER and oxidative stress, mitochondrial dysfunction, and apoptosis (Zhang,  Perry  et  al.  1999;  Mosley,  Benner  et  al.  2006;  Tansey,  McCoy  et  al.  2007; Drechsel and Patel 2008). The diagnosis of PD has classically coincided with the onset of motor  dysfunction manifestations.  Increasing  evidence  lends  support  to  the  belief 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that  non‐motor  symptoms  antedate  the  presentation  of  motor  symptoms,  including olfactory  dysfunction,  depression,  sleep  abnormalities,  and  constipation  (O'Sullivan, Williams  et  al.  2008).  Research  of  the  past  decades  has  shown  new  insight  into  the world  of  PD,  but  it  has  not,  however,  led  to  the  development  of  a  single  coherent mechanism of nigrostriatal dopaminergic neuronal degeneration.   A  newly  emerging  hypothesis  has  gained  popularity  amongst  researchers:  the ‘multiple hit hypothesis’ (Carvey, Punati et al. 2006; Sulzer 2007). Various studies have implicated complex  interactions between environmental  factors, genetics, and cellular dysfunctions as the underling cause of selective neuronal death seen in PD (Warner and Schapira  2003;  Obeso,  Rodriguez‐Oroz  et  al.  2010).  This  hypothesis  stems  from  the belief  that  a  variety  of  neurotoxins/neurotoxicants  bombard  the nigrostriatal  system, possibly  accumulating  over  time,  exacerbating  any  intrinsic  cellular  dysfunction,  and exploiting underlying genetic factors, leading to the onset of sporadic PD.   Environmental  neurotoxicants  have  gained  increasing  interest  as  major  risk causative factors  in the development of sporadic PD. After a  large twin study failed to support  the  hypothesis  that  genetic  factors  play  a  significant  role  in  sporadic  PD’s etiology (Tanner, Ottman et al. 1999), non‐genetic risk factors have become a target in PD research. Pesticides, inflammatory agents, and heavy metals have been implicated as possible  risk  factors  through  experimental  and  epidemiological  studies  (Di  Monte, Lavasani et al. 2002; Olanow 2004; Cicchetti, Drouin‐Ouellet et al. 2009; Burbulla and Kruger 2011). 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 Chronic  neuroinflammation  has  become  a  ubiquitous  finding  in  both  patients and experimental models of PD, with similar evidence seen in other neurodegenerative diseases:  Alzheimer’s  disease,  Huntington’s  disease,  and  amyotrohic  lateral  sclerosis (Streit, Mrak et al. 2004; Whitton 2007). The brains innate immune system is comprised of glial  cells, namely  the microglia and astrocytes,  though microglia are  thought  to be the main contributors to neuroinflammation (Streit and Kincaid‐Colton 1995; Whitton 2007). Microglia,  the  innate  brain macrophage,  can  become  activated  by  a  variety  of triggers: pathogens, infection, and trauma, as well as other innate immune cells within the  brain.  Though  inflammation  is  an  organism’s  normal  response,  some  types  or modes of  inflammation can be damaging,  leading  to deviations  from CNS homeostatic conditions, which can create  toxic environments  for neurons  leading  to degeneration. During  acute,  short‐lived  circumstances,  inflammatory  mechanisms  help  to  prevent injury  while  promoting  healing.  When  these  inflammatory  mechanisms  become chronically sustained, neuroinflammation can  lead to damage of  the surrounding host tissue.  This  makes  the  role  of  microglia  dichotomous,  as  they  contribute  both  to neuroprotection  as  well  as  neurodegeneration.  The  neuroinflammatory  response  is characterized  by  the  release  of  cytokines  and  chemokines,  reactive  oxygen  species (ROS), and reactive nitrogen species (RNS) (Liu, Gao et al. 2003; Block and Hong 2007). Many  of  these  factors  produced  by  microglia  are  proinflammatory  and  cytotoxic  in 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nature, and can cause the microenvironment surrounding the neurons to become toxic, leading to neuronal degeneration.   Neuroinflammation  activates  the  neuroimmune  system,  and  it  is  through  the neuroimmune  response  and  the  subsequent  release  of  a  number  of  cell  signaling molecules, that neurodegeneration occurs. When neuronal damage leads to the loss of communication  between  neurons  and microglia,  microglia  reach  a  hyperactive  state, due  to being outside of neuronal  control.  It  is believed  that  this  is  the point at which persistent  neuroinflammation  is  reached,  and  present  neuropathologies  are exacerbated (Polazzi and Contestabile 2002).  
Microglia activation and reactive microgliosis 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2008).  The  regions  of  the  CNS  having  the  highest  density  of  microglia  are  the hippocampus, substantia nigra, basal ganglia, and olfactory telencephalon.   Microglia  are  intimately  connected  with  other  cells  in  their  immediate surroundings,  both  the  environment  and  the  expression  of  receptor‐ligand  pairs  on neighboring cells, and the microglia  themselves, will have a strong effect on microglia phenotype  (Ransohoff  and  Perry  2009).  A  variety  of  ligands,  signaling  molecules, receptor expression, and so on determine the state of inactivation of microglia as well as microglia morphology. However, it is important to note that microglia do not go from resting to activated, but proceed from a surveillant state to effector microglia through various modes of progression. Microglia are able to show an early and rapid response to acute neuronal injury or insult, varying cell surface proteins and receptors.  The  CNS  is  considered  immune  privileged  in  that  it  is  self‐regulated,  with peripheral  immune  cells  crossing  an  intact  blood  brain  barrier  (BBB),  active macrophage  and  lymphocyte  regulation  by  neurons  and  glia,  and  immunocompetent microglia directing lymphocytic neuroprotective responses (Carson, Doose et al. 2006; Harry and Kraft 2008). Beyond isolation from the peripheral immune system, the CNS immune privilege includes the ability of the neurons and glial  to regulate the immune responses  within  the  CNS.  Though  all  cell  types  within  the  CNS  are  responsible  for immune  mediated  responses,  microglia  are  poised  for  rapid  responses  to environmental  changes. Able  to realign  themselves  in seconds or minutes and readily produce stimulus‐specific factors and begin transcription of response genes giving rise to functional proteins within hours, microglia are extremely reactive. Microglia can both 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Evidence  supporting  a  role  for  microglia  activation  in  neurodegenerative 
diseases   McGeer  et  al.  was  the  first  researcher  to  suggest  the  involvement  of inflammation  in  PD  after  illustrating MHC  upregulation  in  PD  patients  as well  as  the presence of activated microglia within the substantia nigra (McGeer, Itagaki et al. 1988). Since these findings in 1988, various postmortem studies using brains from PD patients have  shown  extensive  microglial  activation  within  the  nigrostriatal  system  (Whitton 2007;  Hirsch  and  Hunot  2009).  Hunot  and  Hirsch  both  described  the  presence  of activated microglia  expressing  pro‐inflammatory  cytokines  as well  as  inducible  nitric oxide  (iNOS)  and  reactive  oxygen  species  (ROS),  all  of which modulate  neuronal  cell death in PD (Hunot, Boissiere et al. 1996; Hirsch, Hunot et al. 1998; Hirsch and Hunot 2009). Using PET scans, microglial activation was also measured in living PD patients, idiopathic PD, showing increased activation in the pons, basal ganglia, and frontal and temporal cortices (Gerhard, Pavese et al. 2006). Interestingly, the increased microglial activation was apparent in all PD patients, as compared to the healthy controls, and was not  correlated  to  the  patient’s  time  since  PD  onset.  Furthermore,  epidemiological studies have also implicated inflammation in the etiology of PD,  illustrating the ability of  continual  non‐steroidal  anti‐inflammatory  drug  (NSAID)  use  to  lower  the  risk  of developing PD by approximately 46% in humans. Animal studies were used to confirm this data (Chen, Zhang et al. 2003; Chen, Jacobs et al. 2005).   Support  for neuroinflammation  involvement  in PD has  also been  strengthened through  studies  showing  a  link  between  infection  and  neurodegeneration.  Systemic 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infections tend to exacerbate neurodegenerative diseases, pointing towards microglial involvement. Studies have illustrated microglial activation can be induced by systemic infection  in  patients  with  multiple  sclerosis  (MS)  (Perry  2004).  In  patients  with Alzheimer’s  disease  (AD)  worsening  periods  of  dementia  were  exhibited  following infections,  and  deteriorating  symptoms  in  patients  suffering  from  MS  (Cunningham, Wilcockson et al. 2005; Perry, Cunningham et al. 2007).  
Mechanisms of microglial neurotoxicity 
  In the adult brain, microglia are mainly in their ‘resting’ state, characterized by a ramified morphology. As already discussed, microglia in their ‘resting’ state are far from static,  constantly palpating  the environment  removing debris and  responding  to even the  slightest  change  in  their microenvironment. Microglia  have  a  diverse  selection  of extracellular  receptors  in  order  to  respond  rapidly  to  a  variety  of  insults.  These receptors are for endotoxins, cytokines and chemokines, ATP, factors found within the serum,  and mis‐folded  proteins.  These  signaling molecules  can  activate  the microglia directly via toxins, pathogens, or endogenous proteins, or  indirectly through damaged neuronal  signaling.  Even  upon  cessation  of  the  initial  insult, microglia  activation  can persist  through  positive  feedback  from  dying  neurons,  as  well  as  signals  from surrounding glial cells, and self‐perpetuating cycles.   Microglia release a variety of  inflammatory cytokines  including  tumor necrosis factor  (TNFα),  interleukin‐1β  (IL‐1β),  and  IL‐6,  which  have  to  ability  to  amplify  and sustain  inflammatory  responses.  The  levels  of  these  three  cytokines  are  shown  to  be 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 PKCδ is a member of the novel PKC family thus making it a calcium independent isoform,  and  is  ubiquitously  expressed  throughout  an  organism’s  tissues (Leibersperger,  Gschwendt  et  al.  1991).  PKCδ  can be  activated  through  at  least  three different mechanisms: nuclear translocation, proteolytic cleavage, and phosphorylation of a tyrosine residue. This is an oxidative stress‐sensitive kinase and plays a key role in apoptotic cell death in PD (Anantharam, Kitazawa et al. 2002; Kaul, Anantharam et al. 2005).  
 
Figure 3: Schematic of PKCδ (Kanthasamy, Jin et al. 2010)    Recent studies have demonstrated PKCδ is highly expressed in the nigral tissue of  mice.  It  also  colocalizes  with  tyrosine  hydroxylase  (TH),  the  rate‐limiting  enzyme necessary for the production of DOPA, the precursor to dopamine (Zhang, Kanthasamy et al. 2007). These studies also outline another relationship between this kinase and the nigrostriatal  pathway,  showing  PKCδ  negatively  regulates  TH  activity  and  dopamine synthesis. Kanthasamy et al. show a schematic of PKCδ’s structure in Figure 3. 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The  nicotinamide  adenine  dinucleotide  phosphate­oxidase  (NADPH  oxidase) 
complex 
  Reactive oxygen species (ROS) are considered an inevitable byproduct of aerobic metabolism,  typically,  though  there are enzymes which  function as producers of ROS. The NADPH oxidase complex is one such enzyme, and is expressed in microglia, among other  cells within  the  CNS  (Bedard  and  Krause  2007).    ROS  has  become  known  as  a major  contributor  to  damage  within  biological  organisms,  avidly  interacting  with  a variety of molecules including proteins, nucleic acids, carbohydrates, and lipids (Bedard and Krause 2007). There are different isoforms of the enzyme deemed NOX1 – NOX5, all of which are transmembrane, reducing oxygen to superoxide by transporting electrons across  membranes.  NOX2,  also  known  as  gp91phox,  is  one  of  the  most  extensively studied  NOX  isoforms,  and  is  referred  to  as  the  phagocyte  NADPH  oxidase,  showing phagocyte‐specific tissue expression (Sumimoto, Miyano et al. 2005). As microglia have phagocytic tendencies, the focus and discussion will be on NOX2, as the NADPH oxidase complex.   In  order  to  create  superoxide,  electrons  are  first  transferred  from  NADPH  to FAD.  This  first  step  is  regulated  by  the  activation  domain  of  p67phox,  one  of  the cytosolic  subunits  of  the NADPH oxidase  complex  (Nisimoto, Motalebi  et  al.  1999).  A single electron is then transferred to the iron center of the heme group, which can only accept one electron, forcing it to donate its electron to the outer heme so that the inner heme group can accept  the second electron,  from the  initial FADH2 molecule. Oxygen 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hemp,  and  is  an  efficient  NADPH  oxidase  inhibitor  (Stefanska  and  Pawliczak  2008). Though the mechanism of inhibition is not completely understood, it is known that the translocation of p47phox, a cytosolic subunit, is impaired and this subunit is unable to migrate  to  the  membrane  and  activate  the  NOX2  complex  (Peters,  Hiltermann  et  al. 2001; Barbieri, Cavalca et al. 2004).  
Environmental factors and neurodegenerative diseases 
  Upon  discovering  MPTP,  it  became  clear  that  some  neurotoxicants  can reproduce both the neurochemical and pathological features associated with idiopathic Parkinsonism,  through  the  specific  targeting  of  the  nigrostriatal  system.  MPTP  was discovered  after  a  group  of  intravenous  drug  users  unknowingly  injected  themselves with  a  synthetic  analog  of  Demerol,  contaminated  with  MPTP.  These  individuals developed parkinsonism‐like symptoms  that were alleviated with  levodopa  treatment (Langston, Ballard et al. 1983). Since this occurrence, the search for environmental risk factors  began,  and  correlations  between  certain  neurotoxicants,  lifestyles,  and Parkinson’s disease came to light.   Epidemiological  studies  implicate  a  number  of  environmental  risk  factors  that may  increase  an  individual’s  risk  of  developing  Parkinson’s  disease.  The  risk  factors include  agrochemicals  (pesticides,  herbicides,  etc.)  (Liu,  Gao  et  al.  2003),  well‐water consumption, industrial chemicals, certain occupations (e.g. mining, farming, welding), and  heavy  metal  exposure  (Tanner  and  Langston  1990;  Gorell,  Johnson  et  al.  1998; 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Elbaz,  Clavel  et  al.  2009)  and  have  all  been  associated  with  increases  in neurodegeneration.  
Table  1:  Environmental  factors  that  may  play  a  role  in  the  development  of 
neurodegenerative diseases.  
Toxicant Authors (Year) Toxicant Authors (Year) 
Paraquat Liou et al. (1997) Maneb Uversky (2004) 
  Tanner et al. (1990) Organophosphates Costa et al. (2008) 
  
Semchuck et al. 
(1991)   Bhatt et al. (1999) 
Disulfide-based 
fumigants Chapman et al. (1991) Manganese Gorell et al. (1999) 
Fungicides Klaasseen, ed. (2001)   Aschner et al (2007) 
  Costa (2006)   Dobson et al (2004) 
  Meco et al. (1994)   
Latchoumycandane et al. 
(2007) 
Organochlorines Seidler et al. (1996) Mercury Ngim et al. (1989) 
Chlorophenoxy 
Semchuck et al. 
(1993)   Monnet-Tschudi et al. (2006) 
Thiocarbamates 
Semchuck et al. 
(1992) Lead Monnet-Tschudi et al. (2006) 
Carbamates Seidler et al. (1996) Vanadium Afeseh-Ngwa et al (2009) 
Rotenone Uversky (2004) Zinc Negga et al. (2011) 
  Wang et al. (2006) Copper Gorell et al. (1997) 
  Cannon et al. (2009)      
  Paraquat, a pesticide used extensively throughout the world, has been used as a PD  model.  It  is  believed  that  paraquat’s  underlying  mechanism  is  related  to  ROS, whether  directly  or  indirectly  (Berry,  La Vecchia  et  al.  2010),  as well  as  its  ability  to activate  caspase‐3,  which  can  lead  to  apoptosis  (Peng,  Mao  et  al.  2004).  Maneb,  a fungicide,  is  able  to  cross  the  blood  brain  barrier.  Its mechanism  of  action  is  poorly understood,  but  it  is  known  that  it  preferentially  inhibits  mitochondrial  complex  III (Zhang, Fitsanakis et al. 2003). Rotenone, a broad‐spectrum insecticide, has the ability 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to inhibit mitochondrial complex I and has been shown to induce the aggregation of α‐synuclein and  lead  to  the  formation of Lewy bodies (Uversky 2004; Cicchetti, Drouin‐Ouellet  et  al.  2009). Rotenone has  also been  shown  to  activate microglia  and,  at high concentrations,  be  directly  neurotoxic  to  neuron‐enriched  cultures,  void  of microglia (Gao, Hong et al. 2002).   Idiopathic  PD  and  metal  toxicity  has  mostly  revolved  around  the  transition metals  and  their  potential  role  in  neurodegenerative  diseases.  Earle  (1968)  first reported  the  finding  of  increased  iron  in  PD  patient  brains,  with  subsequent  studies showing  this accumulation occurs  in  the pars compacta of  the substantia nigra  (Earle 1968;  Sofic,  Riederer  et  al.  1988;  Dexter,  Wells  et  al.  1989).  Iron  toxicity  may  be achieved  through  increased  accumulation  coupled  with  decreases  in  its  binding capability,  along  with  the  possibility  of  increases  in  the  concentration  of  hydroxyl radicals  via  the  Fenton  reaction,  assuming  both  iron  and  hydrogen  peroxide  are available,  leading  to  oxidative  stress  (Di  Monte,  Lavasani  et  al.  2002).  From  the identification of iron as a potential factor in neurodegeneration, other metals have been studied for their possible role in neurodegenerative disease progression.  
Manganese and neurodegeneration 
  Manganese (Mn), an essential trace element, plays an important role in a number of  biological  processes. Manganese  functions  as  an  essential  cofactor  for  a  variety  of enzymes  critical  for  both  metabolic  and  redox  homeostasis  within  the  CNS. Glycosyltransferase,  pyruvate  decarboxylase,  glutamine  synthetase,  and  superoxide 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dismutase are all dependent upon manganese  to  function properly  (Gonzalez‐Zulueta, Ensz et al. 1998; Keen, Ensunsa et al. 2000; Takeda 2003). Excessive exposure  to Mn, however, has been known to lead to accumulation within the striatum, globus pallidus, and  the  substantia  nigra  resulting  in  a  neurodegenerative  disorder  referred  to  as manganism  (Milatovic,  Zaja‐Milatovic  et  al.  2009).  Epidemiological  studies  have implicated a causal relationship between the risk for Parkinsonian‐like symptoms and increased  environmental  Mn  exposure,  especially  due  to  certain  workplace environments  such  as  welding,  smelting,  and  mining  (Aschner,  Guilarte  et  al.  2007; Zhang, Wong et al. 2009).   When the brain is exposed to Mn, it can be taken up by astrocytes and neurons, the role  for microglia  in Mn toxicity  is poorly understood, the astrocytes acting as the main  storage  site  (Aschner  1999;  Aschner,  Vrana  et  al.  1999).  This  increase  in  Mn concentration, however, can cause an alteration in the release of certain factors, which may elicit an excitatory neurotoxic response (Erikson and Aschner 2003). Additionally, increases  in  iNOS, ROS, proinflammatory prostaglandins, and  inflammatory mediators are  seen  upon  Mn‐induced  neurotoxicity  (Liu,  Gao  et  al.  2002;  Erikson  and  Aschner 2003; Erikson, Dorman et al. 2007).   Postmortem studies of human brains have shown Mn‐induced neuronal damage to  be  prominent  in  the  striatum  as well  as  other  structures  of  the  basal  ganglia,  but preferential targeting of the dopaminergic neurons within the pars compacta is thought to  be  spared  (Perl  and  Olanow  2007).  Manganism  is  also  associated  with  striatal dopaminergic  neuron  integrity  alterations,  causing  decreases  in  dopamine  transport 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function  and/or  dopamine  levels  within  the  striatum  (Milatovic,  Zaja‐Milatovic  et  al. 2009). Collectively, these results lead researchers to believe Mn‐induced neurotoxicity is  associated with  oxidative  damage,  free  radical  production,  neuroinflammation,  and an alteration of the striatal dopaminergic neuronal integrity. 






Abstract Exposure  to  environmental  neurotoxicants  such  as metals  and pesticides  have been  shown  to  trigger  dopaminergic  degeneration;  therefore,  these  chemicals  are considered  potential  risk  factors  of  idiopathic  Parkinson’s  disease  (PD). Neuroinflammation  has  gained  increasing  recognition  as  a  critical  mechanism  for sustained dopaminergic degeneration, and thus a contributing factor in the progression of  PD.  Recent  studies  have  shown  that  exposure  to  manganese  (Mn),  by  itself  or  in combination with  inflammatory  stimuli,  can activate neuroinflammatory  responses  in the nigrostriatal dopaminergic system.  We previously showed that novel PKC isoform PKCδ contributes to manganese‐induced apoptosis.  In the present study, we sought to investigate if PKCδ plays a role in LPS/Mn‐induced inflammatory events.  Low dose Mn exposure  (30μM)  in  the  BV2  microglial  cell  model  potentiated  LPS‐induced  iNOS activation as measured by nitrite release. Also gp91phox protein, a vital component of NADPH oxidase complex, is activated, as evident from increased protein expression as well  as  increased  production  of  intracellular  reactive  oxygen  species  upon  Mn/LPS treatment.  Pretreatment  with  PKCδ  inhibitor  rottlerin  attenuated  Mn/LPS‐induced gp91phox  protein  expression  increase,  suggesting  that  PKCδ  may  have  a  role  in Mn/LPS‐induced  activation  of  NADPH  oxidase  complex.    Mn  treatment  in  primary microglia  obtained  from PKCδ knockout  (‐/‐) mice  showed  a marked decrease  in  the 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levels of cytokines released (IL‐1β, IL‐6, IL‐10, IL‐12, and TNFα) as compared to PKCδ (+/+)  primary  microglial  cells.  Collectively,  these  results  suggest  that  the  PKCδ signaling  pathway may  play  an  important  role  in  regulating  LPS/manganese‐induced key  proinflammatory  events,  including  microglial  activation,  cytokine  release,  and NADPH oxidase complex activity.   
Introduction Parkinson’s  disease  (PD)  is  the  most  common  neurodegenerative  movement disorder,  characterized  by  the  progressive  degeneration  of  nigral  dopaminergic neurons and loss of striatal dopamine (Olanow and Tatton 1999). Neuroinflammatory insult mediated by  sustained microglia  activation has been  increasingly  implicated  in the pathogenesis of PD, along with other neurodegenerative diseases. Throughout  the past  decade,  compelling  studies,  including  human,  primate,  and  animal,  along  with epidemiological  data,  show  neuroinflammation  as  a  self‐perpetuating  pathogenic process contributing to the progression of PD (Whitton 2007).  Microglia  are  the  resident  immune  cells  in  the  brain,  playing  a  key  role  in immune  surveillance  and  injury  repair  (Zhang,  Wong  et  al.  2009).  Exposure  to transition metals such as manganese and iron has been linked to the pathogenesis of PD (Earle  1968;  Di  Monte,  Lavasani  et  al.  2002).  Notably,  recent  studies  show  Mn treatment can induce as well as augment the neuroinflammatory responses  in both  in 
vitro  and  in  vivo  models  (Filipov,  Seegal  et  al.  2005;  Chen,  Ou  et  al.  2006;  Moreno, 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Materials.  Lipopolysaccharide  and  rottlerin  were  purchased  from  Calbiochem  (San Diego,  CA).  Inorganic manganese was  purchased  from  Sigma‐Aldrich  (St.  Louis,  MO). RPMI 1640 and DMEM/F‐12 medium, Hank’s balanced salt solution (HBSS), fetal bovine serum  (FBS),  L‐glutamine,  penicillin/streptomycin,  non‐essential  amino  acids,  and sodium pyruvate were purchased from Invitrogen (Carlsbad, CA). Bradford reagent for protein  assays  was  purchased  from  Bio‐Rad  (Hercules,  CA).  The  Griess  reagent  was purchased  from  Sigma  (St.  Louis,  MO).  The  fluorescent  ROS  probe  2’,7’‐dichlorodi‐hydrofluorescein  diacetate  (DCF‐DA)  was  purchased  from  EMD  Chemicals (Philadelphia, PA). Primary antibodies utilized were gp91phox (mouse monoclonal, BD Transduction  Laboratories,  San  Jose,  CA),  NOSII  (rabbit  polyclonal,  Santa  Cruz Biotechnology,  Inc.,  Santa Cruz, CA),  and β‐actin  (mouse monoclonal,  Sigma, St. Louis, MO). Secondary antibodies, for Western blotting, used were IRDye 800‐conjugated anti‐rabbit  (Rockland  Labs,  Gilbertsville,  PA)  and  Alexa  Fluor  680  conjugate  anti‐mouse (Licor, Lincoln, NE).  
Cell  cultures  and  treatment. BV2 microglia,  an  immortalized mouse microglial  cell line  obtained  from  Dr.  Debomoy  K.  Lahiri  (Indiana  University  School  of  Medicine, Department  of  Psychiatry,  Indianapolis,  IN),  were  cultured  in  RPMI‐1640  medium containing 10% fetal bovine serum, 50 U/ml penicillin, and 50 μg/ml streptomycin and kept  in  a  static  environment  maintained  at  37°C  with  a  humidified  atmosphere containing 5% CO2. Cells were treated in RPMI‐1640 containing 2% FBS and pen/strep 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with  1μg/ml  LPS,  30μM Mn,  and  a  combination  of  the  two,  along  with  a  30  minute pretreatment  of  rottlerin  (1μM).  Primary microglia  from  postnatal mouse  pups were obtained through column‐free magnetic separation outlined in our previous publication (Gordon, Hogan et al. 2011). Briefly, using the EasySep mouse CD11b positive selection kit  from STEMCELL Technologies  (Catalog #18770), magnetic  separation of  confluent mixed  glial  cultures  was  completed  after  14‐16  days  of  incubation.  After  media  was aspirated from each T‐75 flask, 3 ml of 0.25% trypsin was added and flasks were place on  a  rotary  shaker  and  allowed  to  agitate  for  20  minutes.  The  trypsin  reaction  was stopped by adding 3 ml DMEM/F12 complete media, DMEM/F12 containing 10% fetal bovine  serum,  50  U/ml  penicillin,  and  50  μg/ml  streptomycin,  and  a  single  cell suspension,  using  trituration, was  obtained.  Cells were  then  centrifuged  for  6 min  at 200  x  g.  The  magnetic  separation  was  performed  according  to  the  manufacturer’s instruction save the final wash step, which was repeated 3 times in order to achieve a purity  level  of  >97%.  The  purified  microglia  were  grown  in  DMEM/F12  media containing 10% fetal bovine serum, 50 U/ml penicillin, 50μg/ml streptomycin, 2mM L‐glutamine, 100 μM non‐essential amino acids, and 2 mM sodium pyruvate. Cells were kept at 37°C in a humidified incubator with 5% CO2. Cells were treated in DMEM/F12 complete media containing 2% FBS. Cells were treated with 100‐500 ng/ml LPS, 30 μM Mn, or a combination of both, pretreatment of cells was with 1 μM rottlerin 30 minutes prior to treatment with LPS and Mn. 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Nitric oxide detection. Supernatant nitric  oxide  (NO)  concentration was determined indirectly  through  supernatant  nitrite  concentration  quantification  using  the  Griess reagent. BV2  cells were  seeded at  a  concentration of 30,000  cells per well  in 96‐well plates  and magnetically  separated  primary microglia were  seeded  onto  poly‐D‐lysine coated 96‐well plates at 200,000 cells per well. Both cells types were allowed to attach overnight before being treated in 125 μl of medium. Upon the end of the treatment, 100 μl  of  supernatant was  pipetted  from  each well  and  placed  in  a  new  96‐well  plate,  to which was added 100 μl of Griess reagent. The plate was incubated on a plate shaker for 10  minutes  at  room  temperature,  allowing  a  stable  color  to  be  obtained.  Using  a Synergy  2  multi‐mode  microplate  reader  (BioTek  Instruments),  the  absorbance  was read  at  540  nm.  A  sodium  nitrite  standard  curve  was  used  to  determine  nitrite concentration for each sample.  
Intracellular  reactive  oxygen  species  quantification  (iROS).  Production  of intracellular reactive oxygen species (ROS) was determined using the fluorescent probe 2’,7’‐dichlorodihydrofluorescein  diacetate  (DCF‐DA),  following  previously  published protocols  (Zhang,  Wang  et  al.  2005;  Qian,  Gao  et  al.  2007).  Magnetically  separated primary microglia were plated at 50,000 cells per well in poly‐D‐lysine coated 96‐well plates.  Cells  were  treated  in  DMEM/F‐12  complete  media  for  6  and  24  hours,  with pretreatment  with  rottlerin  occurring  30  minutes  before  treatment.  When  the treatment ending time‐point was reached, the medium was removed from the wells and the  cells  were  washed  with  HBSS  three  times.  HBSS  containing  10  μM  DCF‐DA  was 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added to each well  (100 μl) and allowed to  incubate  for 1 hour covered with  foil  in a humidified CO2 incubator at 37°C. (Cells were only place in the middle wells of the 96‐well  plate  and  HBSS  was  placed  in  surrounding  empty  wells  to  help  prevent  non‐specific  fluorescence).  The  intensity  of  the  DCF‐DA  fluorescence  was  read  at  an excitation of 485/20 and an emission of 530/25, again using the Synergy‐2 multi‐mode microplate  reader.  The  control  fluorescent  mean  values  were  subtracted  from  the treatment  groups  fluorescent  values,  to  remove background  fluorescence,  leaving  the increase  in  fluorescence  caused  by  the  different  treatments  as  an  increase  in  iROS (Zhang, Wang et al. 2005; Qian, Gao et al. 2007).  
Cytokine detection and quantification. Magnetically separated microglia were plated at 100,000 cells per well  into poly‐D‐lysine coated 96‐well plates. The microglia were allowed to attach overnight before being treated with 100‐500 ng/ml LPS, 30 μM Mn, or a cotreatment of LPS and Mn, and pretreatment with 1 μM rottlerin 30 minutes prior to treatment  with  LPS+Mn.  The  treatment  was  allowed  to  continue  for  24  hours,  upon which time 50 μl of supernatant was collected from each well and frozen and kept at ‐20°C  until  it  could  be  analyzed.  The  Luminex  bead‐based  immunoassay  system  was used  to determine supernatant  cytokine  levels,  and concentrations were extrapolated using recombinant cytokine standards (Vignali 2000; Gordon, Hogan et al. 2011).  
Western Blotting. BV2 cells were seeded in T75 flasks and treated with 1 μg/ml LPS, 30 μM Mn, or a cotreatment of LPS and Mn. for 24 hours. Rottlerin, 1 μM, was used as a 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30‐minute  pretreatment  before  addition  of  LPS  and  Mn  cotreatment.  Cells  were collected  by  scrapping  after  treatment.  Lysates  were  prepared  from  BV2  cells  using modified  RIPA  buffer  (Pierce  Biotechnology).  Proteins  were  resolved  using  10‐12% SDS‐polyacrylamide  gel  electrophoresis  (SDS‐PAGE)  and  transferred  to  nitrocellulose membranes  overnight.  Non‐specific  binding  sites were  blocked  by  Rockland  blocking buffer for 1 hour. The membrane was incubated with anti‐gp91phox (1:1000 dilution) or  NOS2  (1:200  dilution)  overnight  at  4°C  followed  by  secondary  Alexa  Fluor  680 conjugate  anti‐mouse  or  IRDye  800‐conjugated  anti‐rabbit  (1:10,000  dilution) antibodies  for  1  hour  at  room  temperature.  β‐actin  (1:10,000)  was  probed  for  to determine equal protein loading in each lane. Antibody‐bound proteins were detected using the Odyssey Infrared Imaging System (Li‐Cor Biosciences).   
Data Analysis.  Prism  4.0  software  package  (GraphPad  Software,  San Diego,  CA) was used  for  all  data  analysis.  Data  was  analyzed  using  the  unpaired  student  t‐test  or initially analyzed by one‐way ANOVA  followed by Tukey’s post‐test,  to compare all of the treatment groups. Statistically significant differences were considered if the p‐value was less the 0.05.  
Results 
Determination of non­cytotoxic concentrations of manganese 
  In order to determine a working concentration of Mn, BV2 cells were exposed to various  doses  of Mn.  After  24  hours  the  cells  were  viewed  under  a  microscope  to 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determine if the Mn was toxic (Figure 1).  At levels of 250 μM Mn or higher confluency of  cells  within  these  flasks  was  greatly  decreased,  indicating  an  environment  that  is toxic to the cells, either through cell death or an inability to replicate effectively. From this initial experiment and following what concentrations others have already worked with, a dose of 30 μM Mn was chosen as the working concentration. 
Rottlerin inhibits LPS­induced iNOS activation 
  Rottlerin  is  a  selective  inhibitor  of  PKCδ  (Gschwendt,  Muller  et  al.  1994; Latchoumycandane,  Anantharam  et  al.  2005),  and  was  used  to  pharmacologically inhibit  LPS/Mn‐induced  proinflammatory  events  in  this  study  to  determine  the  role PKCδ  plays.  To  determine  the working  concentration  of  rottlerin  to  use,  an  EC50  for rottlerin’s ability to attenuate LPS‐induced iNOS activation was constructed (Figure 2), and an EC50 of 810 nm was determined, and a working concentration of 1 μM was used in subsequent studies. 
Low  dose  Mn  potentiates  increases  in  iNOS  activity  in  combination  with  LPS, 
rottlerin is able to attenuate iNOS activation in primary microglia 
  Previous studies have discussed a synergistic relationship between Mn and LPS in conjunction with NO production (Filipov, Seegal et al. 2005; Chen, Ou et al. 2006). By quantifying  the  amount  of  nitrite  found  in  the  supernatant,  we  could  indirectly determine  NO  production  and  corresponding  iNOS  activity.  To  ensure  we  could replicate the ability of Mn to potentiate LPS‐induced iNOS activation, we first measure nitrite production in BV2 cells after a treatment time of 24 hours (Figure 3). We found LPS alone could  increase  iNOS activity by approximately 400%, while Mn alone, at 30 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μM, did not cause a statistically significant  increase in iNOS activation as compared to the  control  group.  The  combination  of  LPS + Mn,  however,  increased  iNOS  activation approximately 1500% above the control groups and 1000% above the LPS alone group. This data demonstrates the ability of Mn to potentiate LPS activation when considering nitrite production.   Furthermore,  we  repeated  the  study  in  primary  microglia,  which  is  a  more indicative  model  of  in  vivo  response.  The  trend  of  iNOS  activation  in  the  primary microglia mimicked the trend seen in the BV2 cell line (Figure 4). LPS alone increased supernatant nitrite levels from 0.1 μM to over 1 μM, while low dose Mn had no effect on iNOS activation as compared to the control group. The cotreatment of LPS + Mn further increased nitrite production  to close  to 2 μM, almost doubling  the production seen  in the LPS alone group. Rottlerin  (the  selective PKCδ  inhibitor) was able  to  significantly attenuate  the  LPS/Mn‐induced  increase  in  iNOS  activation,  lending  support  to  the hypothesis that PKCδ plays a role in LPS/Mn‐induced NO production. 
Rottlerin  is  able  to  attenuate  LPS/Mn­induced  increased  protein  expression  of 
NOS2 and gp91phox The protein NOS2, also called iNOS, is the enzyme responsible for the production of NO in conjunction with L‐arginine (Dawson and Dawson 1998). To support the iNOS activation  data  gathered  through  indirect  NO measuring  by  quantification  of  a  main metabolite nitrite, we looked at the expression of the NOS2 protein in BV2 cells (Figure 5a). We see that the expression appears to be increased with LPS alone, while low dose Mn does not seem to have an affect on NOS2 protein expression. There is a significant 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increase in NOS2 protein expression upon treatment with both LPS and Mn, following the relationship seen in the nitrite production assay. Rottlerin was able to bring NOS2 expression levels back down to basal levels, showing a role for PKCδ in iNOS activity. As  increased  ROS  production  can  be  an  extremely  deleterious  inflammatory event  (Ara,  Przedborski  et  al.  1998;  Hirsch  and  Hunot  2009),  we  also  looked  at  the protein expression of one of  the NADPH oxidase complex subunits,  gp91phox,  in BV2 cells  (Figure  5b). We  saw  a  similar  trend  in  gp91phox  protein  expression  as  seen  in NOS2 protein  expression. Using LPS we observe an  increase  in  the gp91phox protein expression (though not statistically significantly), while low dose Mn had no such affect. An  increase  in  gp91phox  protein  expression  was  observed  upon  LPS  and  Mn cotreatment.  Rottlerin  attenuated  the  LPS/Mn‐induced  increase  in  gp91phox  protein expression,  supporting  the  hypothesis  that  PKCδ  plays  a  role  in  LPS/Mn‐induced inflammatory events. 
Rottlerin blocks LPS/Mn­induced cytokine production in primary microglia   As cytokines play an important role in modulating inflammation (Block, Zecca et al. 2007), we performed an experiment  to determine  if PKCδ plays a  role  in LPS/Mn‐induced  release  of  proinflammatory  cytokines.  We  quantified  the  supernatant concentration of five cytokines: IL‐1β, IL‐6, IL‐10, IL‐12, and TNFα (Figure 6). LPS and LPS/Mn  induced  a  significant  increase  in  all  five  cytokines,  while  Mn  showed  no increase  in  cytokine  production.  Rottlerin  was  able  to  significantly  attenuate  the LPS/Mn‐induced cytokine production in four of the five cytokines.  IL‐1β did not show 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any attenuation. This data suggests that PKCδ plays a role in LPS/Mn‐induced cytokine production and subsequent release. 
Microglia  cultured  from PKCδ  knockout  animals  show  a  significant  decrease  in 
iNOS activity as compared to microglia cultured from wild­type animals 
  We  further  solidified  the  idea  that  PKCδ plays  a  role  in  LPS/Mn‐induced  iNOS activity (indirectly measured through nitrite release) using an ex vivo model, obtaining microglia  from wild‐type  and PKCδ  knockout  animals  (Figure  7).  LPS  alone was  only able to significantly increase nitrite production in the microglia cultured from the wild‐type mice.  In both cell  types, PKCδ +/+ and PKCδ  ‐/‐, we observe  the ability of Mn to potentiate  LPS‐induced  iNOS  activation  through  a  significant  increase  in  nitrite production. Though LPS and Mn were able to significantly  increase nitrite production, as compared to the control group, in the absence of PKCδ, the increase was significantly lower  than  what  was  seen  when  PKCδ  was  present  in  the  microglia.  These  results suggest  the  PKCδ  plays  a  role  in  LPS/Mn‐induced  nitrite  production,  and, correspondingly, iNOS activity. 
Microglia  cultured  from PKCδ  knockout  animals  show  a  significant  decrease  in 
cytokine release as compared to microglia cultured from wild­type animals 




  Emerging  evidence  shows  augmentation  of  oxidative  stress  levels  in  the dopaminergic  neuronal  microenvironment  is  a  pivotal  factor  in  the  degeneration  of these  neurons.  These  environmental  changes  can  be  caused  by  microglial neuroinflammatory  responses.  To  determine  if  PKCδ  plays  a  role  in  production  of intracellular ROS (iROS), DCF‐DA, a fluorescent probe, was used to quantify production (Zhang, Wang et al. 2005; Qian, Gao et al. 2007). In this instance, we observed the ability of  both  LPS  and  Mn  (alone)  to  significantly  increase  the  amount  of  iROS  present  in primary  microglia  (Figure  9).  A  further  increase  in  iROS  was  seen  when  cells  were treated with both LPS and Mn, which was almost completed attenuated upon rottlerin pretreatment (Figure 9a). Again, we used microglia cultured from PKCδ knockout and wild‐type mice to further confirm a role for PKCδ in LPS/Mn‐induced iROS production. The results show that iROS production was essentially completely blocked when PKCδ was absent (Figure 9b).  
Discussion   In  this  study,  we  confirm  that  PKCδ  plays  a  role  in  LPS/Mn‐induced neuroinflammation  and  that  Mn  can  potentiate  certain  LPS‐induced  microglial responses.  We  found  that  low  dose  Mn,  alone,  is  not  sufficient  to  elicit  a  complete proinflammatory  response.  Low  doses  of Mn  in  combination with  LPS  can,  however, 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elicit multiple  proinflammatory  responses  including NO production,  iROS production, and the release of various cytokines. Using rottlerin to pharmacologically inhibit PKCδ, we  observe  attenuation  in  supernatant  nitrite,  release  of  four  proinflammatory cytokines, and  the protein expression of NOS2 and gp91phox. To  further substantiate that  PKCδ  plays  a  role  in  LPS/Mn‐induced  proinflammatory  events,  we  repeated  the studies using primary microglia cultured from PKCδ wild‐type and knockout mice. We observed  that  iNOS  activity,  iROS  production,  and  cytokine  release  were  drastically inhibited  in  the  absence  of  PKCδ.  These  results  suggest  that  PKCδ  plays  a  role  in LPS/Mn‐induced inflammation in microglia.   Manganese  is  an essential  trace element, playing a pivotal  role  in  a number of biological processes. Normal Mn concentrations within adult human tissue range from 3  to  20  μM  (Roth  and  Garrick  2003),  with  a  mean  brain  Mn  level  of  0.261  μg/g (Markesbery, Ehmann et al. 1984). Mn concentration differs within the brain dependent upon the region, the putamen and substantia nigra have Mn concentrations of 6.31 and 0.34 ng/mg wet weight, respectively (Zecca, Pietra et al. 1994). When  exposed  to  high  amounts  of  Mn,  an  individual  can  develop  a  disorder known  as  manganism,  which  mimics  many  symptoms  associated  with  Parkinson’s disease. Mn has the ability to cross the blood brain barrier via specific carriers including transferrin and divalent metal transporter 1, as well as through simple diffusion (Yokel and  Crossgrove  2004).  Postmortem  studies  of  PD  patient  brains  show  Mn‐induced neuronal damage in structures of the basal ganglia, with prominent damage seen in the striatum,  however,  preferential  targeting  of  pars  compacta  dopaminergic  neurons, 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which is seen in PD, seems to be spared (Perl and Olanow 2007). Though dopaminergic (DA)  neurons  within  the  pars  compacta  do  not  appear  to  be  preferentially  targeted, alteration  in  striatal  dopaminergic  neuron  integrity  has  been  observed,  leading  to decreases  in  dopamine  transport  function  and/or  striatal  dopamine  levels  (Milatovic, Zaja‐Milatovic  et  al.  2009).  Mn‐induced  neurotoxicity  is  associated  with  oxidative damage,  free  radical  production,  and  neuroinflammation,  all  of  which  have  been implicated in the pathology of many neurodegenerative diseases, including Parkinson’s disease.   Recent  studies  have  investigated  multiple  insult  theories,  believing  that sustained  neuroinflammation  and  subsequent  neurodegeneration  is  a  result  of  the culmination of several factors leading to complex interactions between environmental factors,  genetics,  and  cellular  dysfunctions  (Warner  and  Schapira  2003;  Obeso, Rodriguez‐Oroz et al. 2010). Filipov et al.  (2005) and Chen et al.  (2006) observed the ability  of  Mn  to  modulate  LPS‐induced  inflammation,  touching  upon  the  idea  that interactions  between  environmental  factors  can  increase  the  risk  for neuroinflammatory  events.  Though  the  mechanism  through  which  LPS/Mn‐induced neuroinflammation occurs  is not well  characterized,  especially  the  role  that microglia play.   Microglia are the resident immune cells of the brain, constantly surveying their environment,  playing  vital  roles  in  both  immune  surveillance  and  injury  repair (Kreutzberg  1996).  Microglia  are  able  to  respond  to  toxicant‐induced  insults  more quickly than astroglia, via a faster acting activation kinetic, as well as having the ability 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to  produce  a wider  variety  of  neurotoxic  factors  (Liu,  Gao  et  al.  2003).  These  points suggest  that  microglia  play  a  more  prominent  role,  compared  to  astrocytes,  in  glial activation‐mediated neurodegeneration (Liu, Gao et al. 2003).   Due to DA neuronal sensitivity to oxidative stress, ROS is considered particularly toxic (Jenner and Olanow 1998). When PKCδ was absent, we saw an almost complete inhibition of iROS, when using the microglia cultured from knockout mice (Figure 8b). Not only is a decrease in ROS important due to their deleterious affects on DA neurons, hydrogen peroxide, which is efficiently produced by microglia following Mn treatment (Zhang, Hatter et al. 2007), can react with iron to form cytotoxic oxidative radicals via the Fenton reaction. Iron is highly concentrated in the substantia nigra, a good portion of it bound to neuromelanin, which is thought to play a role in attenuating free radical damage, possibly through its ability to chelate transition metals (Gerlach, Double et al. 2003).  Gerlach  et  al.  (2003)  also  hypothesized  that  an  increase  in  iron  concentration (seen  in  PD  patient  substantia  nigras)  may  saturate  iron‐chelating  sites,  leading  to increases  in  iron and subsequent  increases of  free radical  species.  It  stands  to  reason that decreases in ROS production would also be beneficial in that it would decrease the amount  of  hydrogen  peroxide  available  to  undergo  the  Fenton  reaction,  supporting PKCδ as a possible therapeutic target.   It  is  also  important  to mention  the  ability  of  ROS  and  RNS  to  react with  each other to  further  increase the toxicity of an already cytotoxic environment (Hirsch and Hunot  2009).  Superoxide  anions  can  react  with  NO  to  produce  the  highly  reactive nitrogen  species  peroxynitrite,  which  has  the  ability  to  cause  oxidative  damage  in  a 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Figure  1. Response  of  BV2  cells  to  different  concentrations  of manganese.  BV2  cells were  seeded  into  T‐75  flasks  and  allowed  to  attach  overnight.  The  cells  were  then treated with  different  concentrations  of Mn  to  determine  toxic  concentrations  of Mn becomes  toxic  to  the  cells. We  observed  that  concentrations  of  up  to  100  μM  of Mn showed no visible signs of toxicity based upon cell confluency and appearance. As the concentration of Mn increased to 250 μM and above, cells showed signs of toxicity via detachment and decreases in confluency. 
 
Figure 2. Rottlerin EC50 against LPS‐induced iNOS activity. Using LPS to stimulate iNOS activity, an EC50 curve was constructed to determine the EC50 of rottlerin, in terms of its ability to attenuate LPS‐induced iNOS activation. LPS was used at a concentration of 1  μg/ml,  and  the  doses  of  rottlerin  ranged  from  50  nM  to  5μM  (n=6).  Supernatant nitrite  concentration,  using  Griess  reagent,  was  used  to  indirectly  measure  iNOS activity.  The  EC50  of  rottlerin,  in  attenuating  LPS‐induced  iNOS  activity,  was determined to be 810 nM. 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Figure  3. LPS  and Mn  cotreatment  can  increase  nitrite  production  in  BV2  cells.  BV2 cells  were  treated  for  24‐hours,  before  the  supernatant  was  collected  and  nitrite concentration was determined (n=13). LPS alone was able to significantly increase iNOS activity, while Mn (30μM) had no significant effect on iNOS activity. The combination of both LPS and Mn significantly increased iNOS activity above the control group, as well as above the LPS treated group. These data illustrate that low dose Mn by itself does not elicit an increase in iNOS activity, but is able to potentiate the ability of LPS to increase iNOS  activity  in  BV2  cells.  (***  denotes  a  p‐value  <  0.001  as  determined  by  one‐way ANOVA).  
Figure  4.  LPS/Mn‐induced  nitrite  production  can  be  attenuated  upon  rottlerin pretreatment. Mn was also able to potentiate LPS‐induced nitrite production. Rottlerin (Rott) was able to assuage some of the LPS/Mn‐induced increase in nitrite production. Primary  microglia  were  treated  for  24‐hours,  using  rottlerin  as  a  30‐minute pretreatment (n=9, rott n=8). We observed a significant  increase  in nitrite production upon LPS and LPS+Mn treatment as compared to the control group. Mn treatment and rottlerin alone treatment, however, did not  increase nitrite production. When Mn was used  in  conjunction  with  LPS  it  was  able  to  potentiate  the  LPS‐induced  nitrite production  increase.  (**  denotes  a  p‐value  <  0.01,  ***  denotes  a  p‐value  <  0.001  as determined by unpaired t‐test). 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Figure  5.  Expression  of  NOS2  and  gp91phox  are  increased  with  LPS/Mn  treatment, which rottlerin is able to attenuate. BV2 cells were treated in T‐75 flasks for 24‐hours, using  rottlerin  as  a  30‐minute  pretreatment  in  one  group  (n=3).  Figure  5a.  shows densitometric  analysis  of  NOS2  protein  production.  It  appears  that  LPS  treatment increases  expression  of  NOS2,  while  Mn  has  no  effect  on  NOS2  protein  expression. Using  both  LPS  and  Mn,  we  see  a  significant  increase  in  the  expression  of  NOS2, correlating  well  to  our  findings  in  iNOS  activity.  Rottlerin  was  able  to  return  NOS2 protein  expression  levels  back  down  to  near  basal  levels.  Figure  5b.  shows densitometric analysis of gp91phox (a membrane bound subunit of the NADPH oxidase complex) protein expression. Following the trend seen with NOS2 protein expression, it appears  LPS  treatment  increases  gp91phox  expression,  though  no  significance  was found  statistically,  while  Mn  treatment  did  not  seem  to  effect  gp91phox  protein expression.  LPS+Mn  was  able  to  significantly  increase  the  expression  of  gp91phox, while rottlerin was able to significantly attenuate this increase in expression. (* denotes p‐value < 0.05, ** denotes p‐value < 0.01 as determined by unpaired t‐test).  
Figure  6.    LPS/Mn  treatment  was  able  to  increase  cytokine  release  in  primary microglia.  Rottlerin  was  able  to  decrease  LPS/Mn‐induced  increases  in  4  of  the  5 cytokines  in  the  assay.  Cells  were  treated  for  24‐hours,  rottlerin  was  used  as  a  30‐minute pretreatment. Five cytokines were probed for: TNFα, IL‐6, IL‐1β, IL‐10, and IL‐12 (n=4). We observed that Mn did not increase cytokine production and release, while LPS/Mn  caused  a  significant  increase  in  cytokine  release.  Rottlerin  was  able  to 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significantly block release of four of the cytokines, it was not able to block the LPS/Mn‐induced increase in IL‐1β release. (* and *** denote p‐value < 0.05 and p‐value < 0.001, respectively, as determined by one‐way ANOVA).  
Figure  7. An  attenuation  in  nitrite  production  is  seen  in  the  absence  of  PKCδ  using microglia cultured from wild‐type and PKCδ knockout mice, treated for 24‐hours (n=6). The PKCδ +/+ group shows a significant increase in nitrite production upon treatment with LPS, Mn, and LPS+Mn, as well as potentiation between LPS and Mn. In the PKCδ ‐/‐ group, we  only  see  a  significant  increase  in  nitrite  production  in  the  LPS+Mn  group, which is significantly lower than the amount of nitrite produced by PKCδ +/+ microglia undergoing the same treatment. (*, **, and *** denote p‐values < 0.05, 0.01, and 0.001, respectively. All values determined using unpaired t‐test). 
 
Figure  8.  Cytokine  release  is  attenuated  in  the  absence  of  PKCδ.  Using  microglia cultured  from  wild‐type  and  PKCδ  knockout  mice,  we  were  able  to  observe  an inhibition  in cytokine release  in the absence of PKCδ. Both cell  types were treated for 24‐hours  before  the  supernatant  was  collected  and  later  assayed  for  cytokine concentration (n=2). Here, we observe that  in the absence of PKCδ cytokine release is significantly  blocked  in  all  five  cytokines  for  both  LPS  and  LPS+Mn  treatments.  (*** denotes p‐value < 0.001 as determined by one‐way ANOVA). 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Abstract Neuroinflammation  has  gained  increased  recognition  as  a  critical  factor  in neurodegeneration,  specifically  dopaminergic  degeneration,  and  thus  a  contributing factor  to  the  progression  of  Parkinson’s  disease  (PD).  Activation  of  microglia  can instigate neuroinflammatory events leading to neurotoxicity through various molecular signaling pathways. In our study, we investigate the ability of diapocynin, an apocynin metabolite,  to  block  the  neuroinflammatory  response  caused  by  lipopolysaccharide (LPS),  a  known  inflammatory  stimulant.  Using  BV2  microglia  cells  (an  immortalized mouse  microglia  cell  line)  and  primary  microglia  we  characterized  the  anti‐inflammatory  effects  of  diapocynin  against  LPS‐induced  neuroinflammation.  We compare  the  efficacy  of  diapocynin  to  apocynin  in  each  compounds  ability  to  block specific neuroinflammatory events.  First, the EC50 of each compound was determined by blocking LPS‐induced iNOS activity. We found that the EC50 of diapocynin was about eight  times  less  than  that  of  apocynin.  From  this  data,  we  established  the concentrations, for each compound, to be used for the rest of the studies. We focused on key  neuroinflammatory  events:  release  of  a  variety  of  cytokines,  reactive  oxygen species (ROS), and reactive nitrogen species (RNS). 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First  we  show  that  diapocynin,  at  a  concentration  of  10  μM,  is  as  effective blocking  LPS‐induced  iNOS  activation  as  apocynin,  at  a  concentration  of  100  μM. Diapocynin blocked the release of key inflammatory cytokines: IL‐1β, IL‐6, IL‐10, IL‐12, and TNFα. Next we looked at ROS production by looking at intracellular ROS (iROS) and the  expression  of  a  protein  subunit  of  the  NADPH  oxidase  complex.  We  found  that diapocynin  was  able  to  decrease  gp91phox  protein  expression more  effectively  than apocynin  in  LPS  stimulated  BV2  microglia  cells.  Together,  all  the  gathered  data  and results  suggest  that  diapocynin  has  the  potential  to  be  a  therapeutic  agent  against neuroinflammation.  
Introduction   Neuroinflammation  has  gained  increasing  recognition  as  a  critical  factor  in neurodegeneration,  specifically dopaminergic  (DA) neuronal degeneration, and  thus a contributing factor to the progression of Parkinson’s disease (PD). Apocynin, a naturally occurring  methoxy‐substituted  catechol,  has  been  used  experimentally  as  a  NADPH oxidase  inhibitor  (Simons,  Hart  et  al.  1990;  Stefanska  and  Pawliczak  2008).  By inhibiting  NADPH  oxidase  assembly,  apocynin  can  decrease  the  production  of superoxide  from  microglia.  DA  neurons  are  extremely  sensitive  to  oxidative  stress (Jenner  and  Olanow  1998),  showing  that  blocking  production  of  ROS  is    a  pertinent therapy  in  the prevention of  neurodegeneration.    Though  the mechanism has not  yet been  completely  elucidated,  it  is  believed  that  apocynin  impairs  the  translocation  of p47phox,  a  cytosolic  component  of  NADPH  oxidase,  to  the  cell  membrane  (Peters, 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 In order  to determine working concentrations  for diapocynin and apocynin, as well as to directly compare the efficacy’s of each compound we created EC50 curves of each compound in terms of blocking LPS‐induced iNOS activation. Using BV2 cells, we induced  nitrite  production  using  LPS.  We  found  the  EC50  of  diapocynin  to  6.8  μM, almost  eight  times  lower  than  apocynin’s  EC50,  54.4  μM  (Figure  1).  From  this,  we determined working concentrations for diapocynin and apocynin of 10 μM and 100 μM, respectively. 
Diapocynin inhibited LPS­induced iNOS activation more effectively than apocynin 
  Using BV2 cells  (Figure 2a) and primary microglia  (Figure 2b), we assayed  for iNOS  activity  indirectly  through  measurement  of  supernatant  nitrite  concentration. Both  apocynin  and  diapocynin  were  used  as  30‐minute  pretreatments,  and  the  cells were then treated with LPS for 24‐hours. We observe close to a 1200% increase in iNOS 
 64 
activation upon LPS treatment, which  is significantly attenuated with both diapocynin and apocynin pretreatment. The data also shows diapocynin is 10 times as effective as apocynin at blocking LPS‐induced iNOS activation, as it was used at a concentration 10 times less than that of apocynin and both showed a similar iNOS activation inhibition. 
Diapocynin effectively attenuates LPS­induced iROS production   Primary microglia were treated for 24‐hours with LPS and diapocynin as a 30‐minute  pretreatment  (Figure  3).  LPS  efficiently  caused  the  cells  to  increase  ROS production  and  sustain  this  production  over  24 hours.  Pretreatment with  diapocynin effectively blocked all iROS production, bringing iROS concentration below basal levels. 
Diapocynin blocked the LPS­induced release of specific cytokines as effectively as 
apocynin, in primary microglia   Using LPS we were  able  to  elicit  an  increase  in  cytokine  release  from primary microglia.  LPS  treatment  was  allowed  to  run  for  24  hours,  while  diapocynin  and apocynin were both used as 30‐minute pretreatments (Figure 4). Both diapocynin and apocynin were able to inhibit LPS‐induced cytokine release of four or the five cytokines assayed  for:  IL‐1β,  IL‐10,  IL‐12,  and  TNFα.  Neither  compound was  able  to  block  the release of IL‐6. Again, we observe the ability of diapocynin to block cytokine release as well as apocynin, at a lower concentration. 
Diapocynin is able to decrease gp91phox protein expression 
  Gp91phox is the one of the two NADPH oxidase membrane bound subunits. The NADPH oxidase  complex  is  one of  the main  contributors  to ROS production, which  is extremely deleterious in neural environments. Using Western blotting, we see 24‐hour 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LPS  treatment  causes  a  significant  increase  in  gp91phox  protein  expression.  This increased  protein  expression  can  be  attenuated  upon  diapocynin  pretreatment  (30‐minute)  (Figure  5).  However,  apocynin  is  unable  to  block  LPS‐induced  increases  in gp91phox  expression  at  a  concentration  of  100  μM  compared  to  diapocynin’s  10  μM working concentration.  
Discussion   In  this  study we  characterize  the  ability  of  the  novel  compound diapocynin  to inhibit proinflammatory events that have been linked to progressive neurodegenerative diseases.  Apocynin,  a  known  NADPH  oxidase  inhibitor,  is  the  parent  compound  of diapocynin, and was used in some of the assays as a comparison compound. We found the EC50 of diapocynin to be approximately eight times less than the EC50 of apocynin, in terms of blocking LPS‐induced iNOS activity, 6.80 μM versus 54.37 μM respectively. For the remainder of the experiments we used diapocynin at a concentration of 10 μM and apocynin at  a  concentration of 100 μM. We observed  the ability of diapocynin  to inhibit LPS‐induced iNOS activity, cytokine release, and gp91phox protein expression as well as or more effectively than apocynin, even with a working concentration 10 times less.   Recent research has shown that sustained inflammation may play a pivotal role in the development and progression of various neuroinflammatory diseases,  including Parkinson’s disease, Alzheimer’s disease,  and Huntington’s disease  (Streit, Mrak et  al. 2004; Whitton  2007). Microglia,  one  of  the main  contributors  to  neuroinflammation, 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are part of the brain’s innate immune system (Streit and Kincaid‐Colton 1995; Whitton 2007).  Activation  of  microglia  occurs  in  response  to  a  variety  of  triggers  including pathogens,  infection,  and  trauma,  leading  to  a  normal  immune  response.  This inflammatory response is normally transient, providing inflammatory mechanisms that help to prevent injury while promoting healing. When these inflammatory mechanisms become  chronically  activated,  and  neuronal  control  over  microglia  is  lost  due  to neuronal damage,  the microglia  reach a hyperactive  state. At  this point,  it  is  believed that  persistent  neuroinflammation  is  reached,  exacerbating  present  neuropathologies (Polazzi and Contestabile 2002). This neuroinflammatory response is characterized by the release of various factors  including cytokines and chemokines, ROS, and RNS (Liu, Gao et al. 2003; Block and Hong 2007), many of which are produced by microglia.   All  of  the  proinflammatory  factors  released  during  the  neuroinflammatory response  can  by  cytotoxic  in  nature,  causing  a  toxic  neuronal  microenvironment. Though  in  particular,  oxidative  stress  is  extremely  deleterious  to  dopaminergic  (DA) neurons, as they are very sensitive to it (Jenner and Olanow 1998), but DA neurons also tend to produce abundant quantities of ROS (Whitton 2007) due to dopamine content. Oxidative  stress  is  reached when  endogenous  antioxidant  systems  are  saturated  and can  no  longer  handle  the  amount  of  ROS  being  generated.  The  brain  appears  to  be extremely  susceptible  to  oxidative  stress  owing  to  its  excessive  oxygen  demands (Halliwell  2001).  Under  normal  physiological  conditions,  low  levels  of  ROS  are generated,  but  are  scavenged  by  endogenous  antioxidants  including  superoxide dismutase,  glutathione  peroxidase,  and  catalase  as  well  as  by  small  molecules  like 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vitamin C and E (Halliwell 2001; Halliwell 2006). ROS can wreak havoc on a variety of macromolecules,  irreversibly  modifying  them  through  oxidation.  Proteins, carbohydrates, lipids, and DNA are all at risk of ROS mediated modification. All of these points  make  antioxidants  extremely  appealing  therapies  for  neurodegenerative diseases.   Nitrosative stress can also give rise to a cytotoxic environment. Nitric oxide (NO) is an important signaling molecule within the brain, and is necessary for normal brain function.  Increases  in  both  ROS  and  NO  can  lead  to  the  generation  of  a  secondary oxidizing  specie  peroxynitrite,  as  well  as  peroxynitrous  acid.  Peroxynitrite  has  the ability  to  cause  oxidative  damage  in  numerous proteins  namely  tyrosine  hydroxylase (an enzyme necessary for dopamine production) and α‐synuclein (Ara, Przedborski et al.  1998;  Przedborski,  Chen  et  al.  2001;  Hirsch  and  Hunot  2009).  Increases  in production  of  ROS  can  also  lead  to  a  loss  of  NO  bioavailability,  which  can  disrupt pathways that use NO as a signaling molecule. We show diapocynin is able to attenuate both nitrite release and intracellular ROS production (Fig.2, Fig.3).   In  Figure  4, we  show  diapocynin’s  ability  to  block  the  release  of  all  cytokines assayed for excluding IL‐6. IL‐6 is classically thought of as a proinflammatory cytokine, though  studies  have  shown  that  IL‐6  actually  has  anti‐inflammatory  as  well  as regenerative activities (Tilg, Trehu et al. 1994; Opal and DePalo 2000; Scheller, Chalaris et al. 2011). It has also been shown that IL‐6 down‐regulates the synthesis of IL‐1 and TNFα, while having little effect on IL‐10, which is technically the functional definition of an anti‐inflammatory cytokine (Libert, Takahashi et al. 1994; Xing, Gauldie et al. 1998). 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Though  IL‐6  is  still  considered  a  marker  for  systemic  activation  of  proinflammatory cytokines (Barton 1997), playing a pivotal role in acute‐phase protein response, it also plays  a  role  in  modulating  the  immune  response  through  both  pro‐  and  anti‐inflammatory events (Barton, Shortall et al. 1996).    In conclusion, these data demonstrate the ability of diapocynin, a metabolite of apocynin,  to  efficiently  block  LPS‐induced neuroinflammation  in  a  cell  culture model. Our study  first compares  the EC50 of diapocynin  to apocynin,  in  their ability  to block LPS‐induced iNOS activity, and find diapocynin to be an almost eight times more potent inhibitor.  Using  working  concentrations  of  10  μM  for  diapocynin  and  100  μM  for apocynin, we find diapocynin is just as effective at inhibiting the release of IL‐1β, IL‐10, IL‐12, and TNFα, as well as the LPS‐induced increases in gp91phox protein expression. Diapocynin also efficiently attenuated  the  increase  in  iROS production seen upon LPS treatment.  Collectively,  these  results  indicate  that diapocynin  is  a more  efficient  anti‐inflammatory  than  apocynin,  and  may  have  potential  therapeutic  usefulness  in neuroinflammatory disorders. 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Figure Legend 
Figure1.  Diapocynin  is  a  more  effective  inhibitor  of  iNOS  activity.  LPS  was  used  to induce iNOS activity in BV2 cells in order to create dose‐response curves and determine an  EC50  for  each  apocynin  (apo)  and  diapocynin  (diapo).  LPS  was  used  at  a concentration of 1 μg/ml, and various doses of apocynin (Fig. 1b) and diapocynin (Fig. 1a) (n=8). INOS activity was indirectly measured via supernatant nitrite concentration. An  EC50  of  54.37  μM  and  6.80  μM  was  obtained  for  apocynin  and  diapocynin, respectively.  
Figure  2. Diapocynin  can  inhibit  nitrite  release more  efficiently  than  apocynin.  LPS‐induced  iNOS  activation was  attenuated  using  both  diapocynin  (diapo)  and  apocynin (apo)  in both BV2  cells  (n=17,  diapo  and  apo n=8)  and primary microglia  (n=7).  LPS was  used  as  a  24‐hour  treatment,  both  diapocynin  and  apocynin  were  used  as  30‐minute pretreatments. Diapocynin was used at a concentration of 10 μM and apocynin at  a  concentration  of  100  μM.  We  observed  that  both  compounds  were  able  to significantly  reduce LPS‐induced  iNOS activity. These data  indicate  that diapocynin  is more effective  at blocking  this  increase  in  iNOS activity  than apocynin. Neither diapo nor  apo  effected  iNOS  activation when  used  alone  (***  denotes  a  p‐value  <  0.001  as determined by one‐way ANOVA).  
Figure  3.  Diapocynin  is  able  to  inhibit  production  of  intracellular  ROS  (iROS).  The fluorescent probe DCF‐DA was used to assay for iROS. Primary microglia were treated 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with LPS  for 24‐hours and diapocynin (diapo) was used as a 30‐minute pretreatment (n=6). We observe LPS can increase MFI from essentially 0 to over 6000 and the ability of diapocynin to bring it back down to almost below basal level. Diapo used alone had no effect on iROS production. (*** denotes a p‐value < 0.001, as determined by one‐way ANOVA).  
Figure  4. Diapocynin  was  able  to  block  LPS‐induced  cytokine  release  of  4  or  the  5 cytokines quantified. Cells treated with LPS for 24‐hours, using diapocynin (diapo) and apocynin (apo) as a 30‐mintue pretreatment (n=4). Five cytokines were assayed for: IL‐1β,  IL‐6,  IL‐10,  IL‐12,  and  TNFα.  LPS  efficiently  increased  the  release  of  all  five cytokines.  Both  diapo  and  apo  significantly  inhibited  the  release  of  four  of  the  five cytokines,  neither  was  able  to  attenuate  the  release  of  IL‐6.  (***  denotes  p‐value  < 0.001, as determined by one‐way ANOVA).  
Figure 5. Diapocynin  is  able  to attenuate LPS‐induced  increases  in gp91phox protein expression.  Western  blotting  was  used  to  quantify  the  expression  of  the  protein gp91phox. BV2 cells were seeded  into T‐75  flasks and  treated with LPS  for 24‐hours, using apocynin (apo) and diapocynin (diapo) as 30‐minute pretreatments (n=3). Using densitometric  analysis,  we  normalize  the  bands  to  the  β‐actin  band.  LPS  is  able  to significantly  increase  the  expression  of  gp91phox.  Diapo  significantly  blocked  LPS‐induced  increase  in  gp91phox protein  expression while  apo did not have much of  an effect.  Again  we  see  the  ability  of  diapo  to  attenuate  a  proinflammatory  event more 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Abstract Sustained  neuroinflammation  has  become  increasingly  evident  as  a  causative factor  in  the  progression  of  many  neurodegenerative  diseases  including  Parkinson’s disease (PD). Exposure to environmental neurotoxicants such as metals and pesticides are considered potential risk factors in the pathogenesis of PD. Microglia are an integral part  of  the  innate  immune  system  of  the  CNS  and  are  capable  of  producing  rapid neuroinflammatory responses when exposed to pathogens or neurotoxic insults. Metal exposure has been shown to trigger activation of both microglia and astroglia in order to  counter  neurotoxic  insults.  Recently,  studies  have  shown  that  manganese  (Mn) exposure  by  itself  or  in  combination  with  other  inflammatory  stimuli  can  produce neuroinflammatory  responses  in  the  nigrostriatal  dopaminergic  system.  We,  and others,  have  shown  that Mn  can  augment  lipopolysaccharide  (LPS)‐induced  cytokine production,  iNOS  activation,  and  ROS  generation  in  microglial  cells.  In  the  present study,  we  sought  to  investigate  the  anti‐inflammatory  potential  of  a  novel  NADPH oxidase  inhibitor  diapocynin  against  microglial  activation  in  response  to  Mn/LPS‐induced  inflammatory  events.  Diapocynin  treatment  significantly  blocked  Mn/LPS‐induced  iNOS  activation  and  ROS  generation  in  both  primary  microglia  and  BV2 microglia  cell  models.  Measurement  of  cytokine  release  in  the  supernatant  of 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diapocynin  treated  BV2  cell  lines  and  primary  microglia  cells  revealed  that  the compound  effectively  suppressed  the  release  of  TNFα,  IL‐1β,  IL‐6,  IL‐10  and  IL‐12. Expression of  phox proteins,  components  of  the NADPH oxidase  complex  and  a main contributor  to  ROS  production,  was  also  decreased  with  diapocynin  treatment. Collectively, these results suggest that our translational approach with diapocynin can suppress neuroinflammatory events associated with neurotoxic metal exposure.  
Introduction Parkinson’s  disease  (PD)  is  the  most  common  neurodegenerative  movement disorder, but the etiology is currently unknown (Nussbaum and Ellis 2003). The disease is  mainly  characterized  by  the  progressive  degeneration  of  nigral  dopaminergic neurons  and  loss  of  striatal  dopamine.  Neuroinflammation  has  gained  increasing recognition  as  a  critical  factor  in  the  progression  of  neurodegenerative  processes underlying  PD.  Activation  of  microglia  can  instigate  neuroinflammation  leading  to neurotoxicity  through  various  molecular  signaling  pathways.  Throughout  the  past decade,  compelling  studies  have  shown  these  neuroinflammatory  events  to  be  self‐perpetuating  pathogenic  processes  (Block,  Zecca  et  al.  2007).  Therefore,  it  stands  to reason  that  an  anti‐inflammatory  compound  could  be  useful  in  the  treatment  of  PD. Microglia,  one  of  the  resident  immune  cell  types  in  the  brain,  play  a  key  role  in microenvironment  surveillance  and  injury  repair,  mainly  through  the  activation  of inducible  NADPH  oxidase  (NOX2)  (Zhang,  Wong  et  al.  2009).  Therefore,  NOX‐2 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inhibitors  may  be  useful  in  the  treatment  of  PD  through  inhibiting  sustained neuroinflammatory events that can lead to dopaminergic neuronal degeneration.    Exposure to transition metals such as manganese (Mn) and iron has been linked to pathogenesis of PD. Notably, recent studies show Mn treatment can not only induce neuroinflammatory  responses  in  in  vitro  and  in  vivo  models,  but  also  augment  these responses  (Filipov,  Seegal  et  al.  2005;  Chen,  Ou  et  al.  2006;  Liu,  Sullivan  et  al.  2006; Moreno,  Sullivan  et  al.  2008).  We,  and  others,  have  shown  that  Mn  can  augment lipopolysaccharide  (LPS)‐induced  cytokine  production,  NOX‐2  activation,  and  ROS generation in microglial cells.  The plant phenol, apocynin, a naturally occurring methoxy‐substituted catechol has been used by various research groups as a NADPH oxidase inhibitor (Simons, Hart et al. 1990; Stefanska and Pawliczak 2008). The NOX2 NADPH oxidase complex, which is  the  focus of  this paper,  is made up of  five phox proteins as well as  the GTPase Rac. The membrane  bound  subunits  are  gp91phox  and p22phox.  Gp91phox  is  believed  to have  six  transmembrane  domains  comprised  of  various  cytosolic  factors,  and  is considered to be the organizing subunit. The exact role of p22phox is unknown, but it is known that flavocytochrome b558 is a heterodimer consisting of gp91phox and p22phox (Parkos, Allen et al. 1987). The other three phox proteins are cytosolic and translocate to  the  membrane.  The  subunit  p47phox  is  believed  to  organize  the  translocation  of itself  and   p67phox, p40phox,  and GTPase Rac  to  the membrane, where  they  connect with the membrane bound portion of the complex. All of these cytosolic proteins fail to translocate  to  the  membrane  in  the  absence  of  p47phox  (Heyworth,  Curnutte  et  al. 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 Previous  studies  have  outlined  the  ability  of  Mn  to  potentiate  LPS‐induced inflammatory events, such as nitrite production (Filipov, Seegal et al. 2005; Chen, Ou et al.  2006).  Here,  we  determined  diapocynin  can  be  used  as  an  inhibitory  compound, blocking  LPS/Mn‐induced  proinflammatory  events  (Figure  1).  First,  we  observed  the ability  of  Mn  to  potentiate  LPS‐induced  iNOS  activation.  Diapocynin,  used  as  a  30‐minute  pretreatment,  greatly  attenuates  LPS/Mn‐induced  increases  in  iNOS  activity. 
Diapocynin inhibits nitrite production and iNOS activation in primary microglia   We  used  primary  microglia  to  repeat  the  iNOS  activation  study,  as  primary microglia are a more accurate model. The cells were treated with LPS and Mn for 24‐hours, using diapocynin as a 30‐minute pretreatment (Figure 2). Again we observe Mn potentiation  of  LPS  in  terms  of  iNOS  activation  and  nitrite  production. Mn  treatment alone did not stimulate an increase in nitrite production, while it is able to significantly increase  LPS‐induced  nitrite  production,  as  compared  to  LPS  treatment  alone. Diapocynin  is  able  to  significantly  inhibit  nitrite  release,  correlating  to  a  decrease  in iNOS activation, as nitric oxide is a main product of iNOS activity. 
Diapocynin modulates LPS/Mn­induced increase in cytokine release in BV2 cells 
  Using  BV2  cells,  we  probed  for  the  release  of  specific  cytokines  using  the Luminex bead‐based immunoassay. LPS and Mn were used as 24‐hour treatments and diapocynin as a 30‐minute pretreatment. The supernatant was collected and probed for IL‐6, IL‐12, and TNFα (Figure 3). IL‐6 alone shows statistically significant trends, both 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in  terms  of  Mn  potentiation  and  inhibition  of  cytokine  release  through  diapocynin pretreatment. These trends are seen in IL‐12 and TNFα when comparing means, but are were not found significant upon statistical analysis.  
Increased  cytokine  release  in  primary  microglia  upon  LPS/Mn  treatment  is 
inhibited by diapocynin   Primary  microglia  were  used  to  repeat  cytokine  release  analyses  to  better understand  what  might  happen  in  vivo.  Diapocynin  was  first  used  as  a  30‐minute pretreatment,  then  cells  were  treated  in  LPS  and  Mn  for  24‐hours  before  the supernatant was collected. Five cytokines were probed for in the collected supernatant: IL‐1β, IL‐6, IL‐10, IL‐12, and TNFα (Figure 4). The release of IL‐10 was not increased by Mn  treatment,  but  LPS with Mn  significantly  increases  the  release  of  this  cytokine  in comparison  to  LPS  treatment  alone.  Diapocynin  was  able  to  attenuate  the  LPS/Mn‐induced cytokine release in all cytokines except IL‐6. 
Diapocynin attenuates intracellular ROS (iROS) production in primary microglia   Production and  release of ROS are known  to be exceedingly  toxic  to  tissues  in the  surrounding  area  as  it  causes  a  cytotoxic  environment  and  can  exert  deleterious effects  directly  upon  a  cell  (Bedard  and  Krause  2007).  As  ROS  production  can  occur very  rapidly  after  an  insult, we measured  iROS  at  two  time points  to  assess whether diapocynin  could  inhibit  the  production  of  early ROS  as well  as  sustain  its  inhibitory effects over a long period. Using primary microglia, we treated with LPS and Mn for 6‐hours and 24‐hours, using diapocynin each time as a 30‐mintue pretreatment (Figure 5).  Using the fluorescent probe DCF‐DA, we quantified iROS as an MFI. We observe that 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Mn  is  a  more  potent  activator  of  iROS  production  than  LPS.  Instead  of  potentiation between  LPS  and  Mn  in  terms  of  iROS  production,  we  observe  more  of  an  additive relationship,  especially  when  looking  at  the  24‐hour  treatment  group.  Diapocynin  is able  to  inhibit  iROS  production  at  both  6  and  24  hours,  showing  it  is  able  to  work quickly  to  inhibit  iROS  production,  as  well  as  continue  inhibition  through  sustained activity. 
Diapocynin effects on gp91phox protein expression 
  Using Western  blotting  and  BV2  cells,  we  analyzed  the  protein  expression  of gp91phox (Figure 6). Though the results were not statistically significant, we observe an  increase  in  the mean gp91phox protein expression upon  the 24‐hour  treatment of LPS  and  LPS/Mn  treatment.  Diapocynin,  as  a  30‐minute  pretreatment  decreases  the mean gp91phox protein expression near to the basal level mean, if not slightly below. 
Microglia morphology greatly changes upon LPS and LPS/Mn treatment, but can 
be returned to a quiescent morphological state with diapocynin  treatment 
  Primary microglia cells were stained with p67phox, one of the cytosolic subunits of the NADPH oxidase complex, and the nuclear stain Hoechst after 24‐hour treatment with  LPS  and  Mn  and  30‐minute  pretreatment  with  diapocynin  (Figure  7).  We  see morphology consistent with a ‘resting’ state in the control group. Microglia in a ‘resting’ state have more of a ramified morphology, with distinct branches reaching from the cell body  into the environment.  In the LPS group and LPS/Mn groups, we observe a more amoeboid‐like  shape,  consistent  with  activated  microglia  morphology.  The  protein p67phox  follows  a  honeycomb‐like  pattern within  the  cell, with, what  appears  to  be, 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increased  density  at  the  cell  membrane,  which  is  expected  as  p67phox  translocates from the cytosol  to  the membrane  in order  to activate gp91phox. Treatment with Mn alone does not appear to have much effect on morphology, and the cells remain in their ramified  state.  Pretreating  the  cells  with  diapocynin  appears  to  not  only  attenuate p67phox expression, but also keeps the microglia from becoming activated, as they are morphologically similar to the control group cells, as compared to the LPS and LPS/Mn groups’ amoeboid appearance.  
Discussion In  this  study  we  observe  the  ability  of  novel  compound  diapocynin  to  inhibit proinflammatory events associated with LPS/Mn  insult. These  same proinflammatory events  that  are  elicited  upon  insult  with  LPS/Mn  have  been  linked  to neuroinflammation  and  are  believed  to  exacerbate  underlying  neuropathologies (Polazzi  and  Contestabile  2002).  Using  diapocynin  at  a  concentration  of  10  μM,  we observe  its  ability  to  inhibit  iNOS  activation,  cytokine  release,  iROS  production,  and microglial  morphological  changes.  We  also  observe  trends  in  the  expression  of gp91phox,  diapocynin  showing  what  appears  to  be  inhibition  in  gp91phox  protein expression, which appears to be increased upon treatment with LPS and Mn together. The CNS is able to self‐regulate its innate immune system, making it an immune privileged system. It  is necessary for peripheral  immune cells  to cross an  intact blood brain barrier, regulation of macrophages and lymphocytes is actively accomplished by neurons  and  glia,  and  immunocompetent  microglia  are  responsible  for  directing 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lymphocytic  neuroprotective  responses  (Carson,  Doose  et  al.  2006;  Harry  and  Kraft 2008). Astrocytes  and microglia  are  the main  glial  cells  of  the brain’s  innate  immune system, though microglia are believed to be the main neuroinflammatory contributors (Streit  and  Kincaid‐Colton  1995;  Whitton  2007).  Microglia  continually  palpate  their environment,  becoming  rapidly  activated  in  reaction  to  any  environmental  change or trigger  including  pathogens,  infection,  and  trauma.  Microglial  neuroinflammatory responses are characterized by the release of cytokines and chemokines, ROS, and RNS (Liu, Gao et al. 2003; Block and Hong 2007; Block, Zecca et al. 2007), all of which are observed  in  the  present  study.  Microglia  also  undergo  morphological  changes  upon activation,  going  from what  is  considered  a  ‘resting’  state,  though  it  has  been  shown that  microglia  are  continually  active  and  constantly  surveying  their  environment, characterized  by  a  ramified  morphology  to  an  activated  state  characterized  by  an amoeboid‐like  morphology.  We  see  both  morphologies  in  Figure  7,  where  LPS  and LPS+Mn  are  able  to  elicit  an  amoeboid‐like  morphology  consistent  with  activated microglia, which is attenuated when cells are pretreated with diapocynin.  Manganese  (Mn)  is  an  essential  trace  element  playing pivotal  roles  in  various biological  processes,  functioning  as  an  important  cofactor  for  a  variety  of  enzymes. These enzymes are critical  in CNS homeostasis of both metabolic and redox reactions. The  enzymes  glycosyltransferase,  pyruvate  decarboxylase,  glutamine  synthetase,  and superoxide  depend  upon manganese  for  their  ability  to  properly  function  (Gonzalez‐Zulueta,  Ensz  et  al.  1998;  Keen,  Ensunsa  et  al.  2000;  Takeda  2003).  Using  specific 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carriers  including  transferrin  and  divalent  metal  transporter  1  and  through  simple diffusion, Mn is able to cross the blood brain barrier (Yokel and Crossgrove 2004). Exposure  to  high  amounts  of  Mn  can  lead  to  the  development  of  a  disorder known as manganism.  People  afflicted by  this  disorder  display motor  symptoms  that very  closely  mimic  symptoms  associated  with  PD  (Josephs,  Ahlskog  et  al.  2005; Aschner,  Guilarte  et  al.  2007).  Due  to  these  observations,  researchers  began  looking into  the  mechanisms  through  which  Mn  works  and  if  there  may  be  a  connection between  Mn  exposure  and  PD.  Postmortem  studies,  using  PD  patient  brains,  have shown  that  though  Mn‐induced  neuronal  damage  is  prominent  in  the  striatum  and other  structures  of  the  basal  ganglia,  it  does  not  show  preferential  targeting  of  the dopaminergic neurons (Perl and Olanow 2007). High dose Mn does, however, elicit an inflammatory  response,  increasing  iNOS,  ROS,  proinflammatory  prostaglandins,  and other  inflammatory  mediators,  and  alterations  which  can  lead  to  an  excitatory neurotoxic response (Liu, Gao et al. 2002; Erikson and Aschner 2003; Erikson, Dorman et al. 2007). Being that Mn‐induced neurotoxicity is associated with  oxidative damage, free radical production, and neuroinflammation, which have all been implicated in the pathology of numerous neurodegenerative diseases,  including PD,  it  appears  to be an environmental  factor  that  may  play  a  role  in  development  or  exacerbation  of neurodegenerative disorders. Sustained  neuroinflammation  is  believed  to  play  a  pivotal  role  in  the development  and  subsequent  progression  of  many  neurodegenerative  disorders, including  PD  (Streit,  Mrak  et  al.  2004;  Whitton  2007),  demonstrating  that 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neuroinflammation may be an important therapeutic target for PD, Alzheimer’s disease, Huntington’s  disease,  and  many  others.  It  is  also  believed  that  numerous  factors: environmental  factors, genetics, and cellular dysfunction, play a role  in the etiology of neuroinflammatory disorders, known as a ‘multiple hit hypothesis’ (Carvey, Punati et al. 2006; Sulzer 2007), leading to a complex, multi‐factorial etiology of neurodegeneration. In  this  study,  we  show  how  the  compound  diapocynin  can  inhibit  various neuroinflammatory events  associated with LPS/Mn  insult, which  could  correspond  to an increase in neuronal survival in the face of environmental neurotoxicant insult. Dopaminergic  neurons  exhibit  high  sensitivity  to  oxidative  stress, making ROS particularly  toxic  (Jenner  and  Olanow  1998).  Pretreatment  of  cells  with  diapocynin inhibits  iROS  production,  which  was  induced  by  LPS/Mn  treatment  (Figure  5).  This inhibition  was  seen  at  an  early  time  point  of  6  hours,  which  was  chosen  as  ROS production  is  seen  early  in microglial  activation,  and was  sustained  throughout  a  24 hour period.  It  is also  important  to mention that  iNOS activity was also attenuated by diapocynin pretreatment in both BV2 cells (Figure 1) and primary microglia (Figure 2). Superoxide anions and NO, though not extremely reactive by themselves, can react with one  another  to  produce  the  highly  reactive  nitrogen  species  peroxynitrite, which  has the  ability  to  damage  a  variety  of  proteins  through  oxidation  (Ara,  Przedborski  et  al. 1998; Przedborski, Chen et al. 2001; Hirsch and Hunot 2009). In  conclusion,  this  study  demonstrates  the  ability  of  the  novel  compound, diapocynin,  to  attenuate  the  neuroinflammatory  response  elicited  by  treatment  with both  LPS  and Mn. We  show  that  diapocynin  has  the  ability  to  block  LPS/Mn‐induced 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Figure 1. Diapocynin is able to attenuate LPS/Mn‐induced nitrite production. BV2 cells were pretreated with diapocynin  (diapo)  for 30‐mintues before being  treated  for 24‐hours. The supernatant was collected and assayed for nitrite concentration (n=17, n=8 diapo grp), and the results were graphed as a percent of the control level. We observed Mn was able to potentiate the LPS‐induced iNOS activity. Diapocynin pretreatment was able  to  significantly  reduce  LPS/Mn‐induced  iNOS  activation.  (***  denotes  p‐value  < 0.001 as determined by one‐way ANOVA).  
Figure 2. Nitrite production was blocked by diapocynin. Primary microglia were used to show the ability of diapocynin (diapo) to attenuate LPS/Mn‐induce iNOS activation. Primary microglia were seeded into 96‐well plates at 150,000 cells per well and treated for 24‐hours, with a 30‐pretreatment of diapocynin. The supernatant was collected and probed for nitrite (n=9, n=8 diapo grp). Results were graphed as nitrite concentration. Mn potentiation was  seen  in  iNOS  activity, which  diapocynin  is  able  to  attenuate.  (** denotes  p‐value  <  0.01,  ***  denotes  p‐value  <  0.001,  as  determined  by  one‐way ANOVA).  
Figure 3. Diapocynin was able to modulate cytokine release in BV2 cells. BV2 cells were seeded into 96‐well plates at 30,000 cells per well, pretreated with diapocynin (diapo) for 30‐minutes, and  then  treated  for 24‐hours. Supernatant was collected and probed for  IL‐6,  IL‐12,  and TNFα  (n=4).  It  appears  that  LPS  and Mn  are  able  to  increase  the 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release of  each of  the  three  cytokines,  though only  IL‐6  shows  statistically  significant results. We also observe the ability of diapocynin to significantly reduce the amount of IL‐6  and  IL‐12  being  released,  the  same  trend  appears  with  TNFα,  though  no significance  was  found.  (*  denotes  p‐value  <  0.05,  ***  denotes  p‐value  <  0.001  as determined by one‐way ANOVA).  
Figure 4. Diapocynin attenuate LPS/Mn‐induced release of various cytokines. Primary microglia  were  seeded  into  96‐well  plates  at  100,000  cells  per  well.  Cells  were pretreated for 30‐minute with diapocynin (diapo) and then treated for 24‐hours (n=4). The collected supernatant was probed for IL‐1β, IL‐6, IL‐10, IL‐12, and TNFα. Here we observe  the ability of  the LPS+Mn cotreatment  to greatly  increase  the release of each cytokine. Diapocynin is able to attenuate this increase in cytokine release in four of the five cytokines,  IL‐6 release  is unaffected by diapocynin pretreatment. We also see Mn potentiation of LPS‐induced cytokine release  in  IL‐10. (*** denotes p‐value < 0.001 as determined by one‐way ANOVA).  
Figure  5.  Diapocynin  blocked  LPS/Mn‐induced  intracellular  ROS  production.  Using primary  microglia  plate  at  50,000  cells  per  well  in  96‐well  plates,  we  probed  for intracellular ROS (iROS) production at two time points. The fluorescent probe DCF‐DA was used to assay for iROS, which was quantified as MFI. Cells were pretreated for 30‐minutes  before  being  treated  for  6‐hours  and  24‐hours  (n=4).  Here  we  observe  the 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ability of diapocynin to inhibit LPS/Mn‐induced iROS production at both 6 hours and 24 hours. (*** denotes p‐value < 0.001 as determined by one‐way ANOVA).  
Figure 6. Trends in the expression of gp91phox show modulation of LPS/Mn‐induced increase in protein expression by diapocynin. Western blotting was used to observe any changes in the protein expression of gp91phox. BV2 cells were treated in T‐75 flasks for 24‐hours, using diapocynin as a 30‐minute pretreatment (n=3). Densitometric analysis was  done,  normalizing  all  bands  to  the  β‐actin  band. Due  to  cell  variability, we were only  able  to  see  a  significant  increase  in  gp91phox  protein  production  upon  LPS treatment.  It  appears  that  the  cotreatment  of  LPS  and Mn was  also  able  to  increase protein  expression  when  comparing  the  means,  though  no  significance  was  found. Diapocynin  decreases  the  mean  LPS/Mn‐induced  increases  in  gp91phox  expression, though no significance was found. (** denotes p‐value < 0.01 as determined by unpaired t‐test).  
Figure 7. Morphological changes in microglia were visualized. A decrease in activated morphology was  seen with diapocynin  treatment.  Immunocytochemistry was used  to show  microglial  morphological  changes,  as  well  as  p67phox  expression.  Cells  were plated at 150,000 cells per well in 24‐well plates, pretreatment with diapocynin (diapo) was  30‐minutes  with  LPS  and  Mn  treatments  of  24  hours.  We  observed  the  normal ramified morphology  of  ‘resting’ microglia  in  the  control  group,  as well  as  in  the Mn only treatment group, which indicates the low dose of Mn is not activating them. Upon 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LPS  or  LPS+Mn  treatment, we  observe  drastic morphological  changes  as  the  cells  go from  their  ‘resting’  morphology  to  an  amoeboid  like  morphology,  indicating  the microglia  have  become  activated.  The  cells  pretreated  with  diapocynin  show morphology  more  consistent  with  ‘resting’  microglia,  though  they  do  have  a  slight amount of rounding indicating there may be some activation occurring. 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CHAPTER V: GENERAL CONCLUSION    The  etiologies  of  numerous  neurodegenerative  diseases  have  yet  to  be elucidated,  but  neuroinflammation  has  gained  recognition  as  a  critical  contributing factor  to  neurodegeneration.  Neuroinflammatory markers  have  become  a  ubiquitous finding  in patients as well as experimental models of PD. These markers are similarly observed in Alzheimer’s disease, Huntington’s disease, and ALS (Streit, Mrak et al. 2004; Whitton 2007). Therefore, elucidating the complete neuroinflammatory mechanisms is considered  paramount  for  development  of  therapeutic  agents  against neuroinflammation.  Glial  cells,  namely microglia  and  astrocytes, make  up  the  brain’s innate  immune  system,  though  microglia  are  considered  the  main  contributors  to neuroinflammation  (Streit  and  Kincaid‐Colton  1995;  Whitton  2007).  Recently, manganese  (Mn) was  shown  to modulate  and,  in  some  cases,  potentiate  LPS‐induced inflammation (Filipov, Seegal et al. 2005; Chen, Ou et al. 2006). In conjunction with the aforementioned  findings,  the  present  studies  used  a  microglia  cell  culture  model  of neuroinflammation.   In  the  initial  study,  we  investigated  whether  PKCδ  plays  a  role  in  LPS/Mn‐induced inflammation. We first determine that low doses of manganese, alone, are not sufficient  to  elicit  an  inflammatory  response  in  microglia  cell  cultures.  However, manganese in combination with LPS induces a robust response,  including increases in nitrite  and  iROS  production,  and  the  release  of  various  cytokines.  Some  of  these responses  show  Mn  potentiation  of  LPS,  as  seen  with  nitrite  production.  After 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establishing  that manganese and LPS cause  inflammation without killing  the cells, we wanted to determine if PKCδ played any role in the elicited inflammatory response.   For the initial experiments, we utilized rottlerin, a pharmacological  inhibitor of PKCδ. When cells were pretreated with  rottlerin,  LPS and manganese were unable  to mount  an  inflammatory  response,  similar  to  the  effect  in  cells  that  had  not  been subjected  to  rottlerin  pretreatment.  To  determine  if  the  nitrite  production  observed was  a  result  of  iNOS activity, NOS2 protein  expression was quantified. We  found LPS treatment alone was unable  to  increase protein expression significantly,  though  there was  an  increase  in  the  mean  expression,  but  Mn  potentiation  caused  a  significant increase  in  NOS2  protein  expression.  Rottlerin  pretreatment  significantly  attenuated the  protein  expression  increase  seen  following  LPS/Mn  treatment, which  follows  the observed trend of nitrite production. To further solidify PKCδ’s role in LPS/Mn‐induced nitrite production, we preformed ex vivo experiments on microglia cultured from wild‐type  and  PKCδ  knockout mice.  Following  the  trends  seen with  rottlerin  inhibition  of PKCδ, we saw a significant decrease in nitrite production in the absence of PKCδ.    Oxidative  stress  is  particularly  toxic  to  dopaminergic  neurons  making  it  an important therapeutic target (Jenner and Olanow 1998). We observed intracellular ROS (iROS)  production  to  determine  a  role  for  PKCδ.  Mn  treatment  elicits  a  robust production of hydrogen peroxide, more  so  than LPS  treatment alone. Treatment with both LPS and Mn caused an even greater production of iROS, which was blocked when cells were pretreated with  rottlerin.  To  further  solidify  these  findings, we used  an ex 
vivo model,  culturing microglia  from wild‐type  and PKCδ  knockout mice. We  found  a 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near  complete  block  of  iROS  production  in  the  absence  of  PKCδ.  In  addition,  no difference was observed between  treatments,  showing Mn  is unable  to modulate LPS iROS production stimulation when PKCδ is not present.   Cytokines play an  important  role  in  the  immune  response. Using  rottlerin as a PKCδ  inhibitor, we were able  to block  the release of TNFα,  IL‐6,  IL‐10, and  IL‐12, but saw no change  in  the  supernatant  levels of  IL‐1β. We  repeated  this  experiment using microglia  cultured  from  wild‐type  and  PKCδ  knockout  animals.  With  the  PKCδ  gene completely removed, we saw similar results, except IL‐1β release was also attenuated.    These  results  demonstrate  that  PKCδ  plays  an  important  role  in  LPS/Mn‐induced neuroinflammation. Blocking PKCδ activity greatly decreases proinflammatory events in microglia, while completely knocking out the PKCδ gene further decreases the same  proinflammatory  events.  Collectively,  these  results  indicate  PKCδ  is  a  potential therapeutic target against neuroinflammatory events.     Next, we wanted to determine the therapeutic efficacy of a novel NADPH oxidase compound, diapocynin. Apocynin,  a naturally occurring methoxy‐substituted catechol, has been used experimentally as an NADPH oxidase inhibitor (Simons, Hart et al. 1990; Stefanska and Pawliczak 2008). The NADPH oxidase complex is the main contributor to ROS  production,  and  therefore  an  attractive  target  molecule  in  the  prevention  of inflammation. Apocynin converts into a dimer through peroxidase‐mediated oxidation, to  become  an  active  metabolite  (Stefanska  and  Pawliczak  2008).  Our  laboratory synthesized diapocynin through oxidative coupling of apocynin. We hypothesized that 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the  already  dimerized  form  of  apocynin  would  be  a  more  potent  inhibitor  of proinflammatory events caused by LPS insult.    We  found  diapocynin  more  efficiently  blocked  LPS‐induced  iNOS  activation, with  an  EC50  of  6.80  μM  compared  to  apocynin’s  EC50  of  54.37  μM.  We  showed diapocynin is a more effective inhibitor of nitrite production and cytokine release than apocynin.  Diapocynin  attenuated  LPS‐induced  increases  in  gp91phox  protein expression,  while  apocynin  had  no  effect  on  protein  expression.  Diapocynin  also reduced LPS‐induced iROS production to below basal levels.   Though the mechanism through which diapocynin acts has yet to be elucidated, we  show  that  diapocynin  is  a  more  efficacious  inhibitor  of  LPS‐induced proinflammatory events as compared to apocynin. Diapocynin effectively inhibits LPS‐induced nitrite production, iROS production, and the release of IL‐1β, IL‐10, IL‐12, and TNFα.  Collectively  these  date  suggest  diapocynin  is  a  more  potent  NADPH  oxidase inhibitor  than  apocynin,  and  has  the  potential  to  be  a  therapeutic  agent  against neuroinflammation.   Next  we  determined  the  ability  of  diapocynin  to  attenuate  LPS/Mn‐induced neuroinflammatory  events.  Since  Mn  has  the  ability  to  modulate  proinflammatory events  caused by  LPS  insult, we wanted  to  establish  if  diapocynin  is  still  an  effective inhibitor  of  nitrite  release,  iROS  production,  and  cytokine  release  when  cells  are cotreated with  LPS  and Mn. We  hypothesized  that  diapocynin  can  dampen microglia induced inflammatory events. 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 Initially, we wanted to assess diapocynin’s ability to attenuate LPS/Mn‐induced iNOS  activation.  We  observe  diapocynin  effectively  blocks  LPS/Mn‐induced  iNOS activation, which follows the trend seen in the previous studies investigating LPS alone. We observed these results in both BV2 cells and primary microglia. We then assayed for cytokines  using  both  the  BV  cell  and  primary  microglia  cell  models.  Diapocynin attenuated  LPS/Mn‐induced  release  of  IL‐6  and  IL‐12  significantly;  however,  TNFα release was not attenuated significantly, though we did see a large decrease in the mean cytokine  release.  BV2  cells  show  great  variation  between  stocks,  leading  to  variation between replicates and increased error bars, which could be the reason no significance was observed between treatment groups. Diapocynin did, however, significantly block the  release  of  IL‐1β,  IL‐10,  IL‐12,  and  TNFα  in  the  primary microglia  cell  model.  No change was seen in IL‐6 release with diapocynin pretreament.   Intracellular  ROS  production  was  measured  at  both  6  hours  and  24  hours. Diapocynin  pretreatment  attenuated  LPS/Mn‐induced  iROS  production  at  each  time‐point,  showing  that  its  anti‐inflammatory  effects  begin  early  and  are  sustained throughout the treatment. Along with iROS production, we assessed gp91phox protein expression.  Though  we  did  not  find  any  significant  changes  in  gp91phox  protein expression  across  the  different  treatment  groups,  we  observed  a  trend  in  the  mean protein expressions. The trend shows an increase in gp91phox protein expression with LPS/Mn treatment, which is attenuated with diapocynin pretreatment.   Using primary microglia, we also visualize changes in cell morphology caused by LPS/Mn insult.  In the control group we observe a morphology that  is more consistent 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with microglia  in their  ‘resting state’. The LPS and LPS/Mn treated microglia show an amoeboid‐like  morphology  consistent  with  morphology  seen  in  activated  microglia, which  is  expected.  Pretreating  the  cells  with  diapocynin  appears  to  attenuate  these morphological changes, leaving cells that more closely resemble the morphology of the control  group  cells.  This  lends  support  to  the  hypothesis  that  diapocynin  can  block microglial activation.   This study demonstrates that the novel compound diapocynin has the ability to attenuate microglial  induced  inflammatory  responses  elicited  by  treatment  with  LPS and  Mn.  We  show  diapocynin’s  ability  to  block  the  main  neuroinflammatory characterizing factors: cytokine release and ROS and RNS production. Collectively, these results  indicate  that  diapocynin  may  have  potential  as  a  therapy  against neuroinflammation.   Herein,  we  have  discovered  a  potential  therapeutic  target  for neuroinflammatory  events  in  PKCδ.  We  implicate  PKCδ  in  various  LPS/Mn‐induced microglia inflammatory responses by demonstrating that the absence of PKCδ leads to less  robust  inflammatory  events.  In  addition,  we  have  characterized  the  anti‐inflammatory effects of a novel compound, diapocynin. We show diapocynin is a more effective  anti‐inflammatory  compound  than  its  parent  compound,  apocynin.  We  also show  diapocynin  can  effectively  block  LPS/Mn‐induced  microglia  inflammatory responses. 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